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ABSTRACT 
Congenital heart block (CHB) is a rare condition with considerable mortality. In most 
patients the disease is associated with fetal exposure to maternal SSA-Ro and/or SSB-La 
autoantibodies (AB) and develops in fetal life. Accuracy in fetal diagnostics is important 
to distinguish benign from life threatening conditions. Transplacental steroid treatment to 
improve survival has been tried but the effect is unclear. The majority of exposed children 
do not develop CHB, but sometimes transitory conduction abnormalities, normalizing at 
birth, with unknown outcome in childhood. Pacemaker (PM) therapy to CHB patients is 
lifesaving, but does not always prevent development of heart failure.  
 
The aims of this thesis were to study: The differential diagnostics in fetal bradycardia 
(paper I), the effect of transplacental steroid treatment and risk factors associated with a 
poor outcome (paper II), the clinical pathogenesis of antibody exposure (paper III) and 
PM treatment in young patients with complete atrioventricular block (CAVB) (paper IV) 
 
In paper I, the diagnostic accuracy with Echo Doppler techniques was studied 
retrospectively in a regional cohort of 65 patients with fetal bradycardia. We found that 
the bradyarrhythmic mechanism was identified correctly in all but one patient. Benign 
blocked atrial bigeminies showed close resemblance to second-degree AVB in a few 
cases, but could be differentiated with meticulous measurements. 
 
In paper II, the effects of exposure to transplacental treatment with fluorinated steroids in 
fetal second- and third degree AVB were studied retrospectively in a multicenter, 
multinational setting of 175 patients. Ninety-one percent were alive at birth and survival 
rate in the neonatal period was 93%, similar in treated and untreated fetuses. Risk factors 
(RF) associated with a poor outcome were gestational age < 20 weeks, ventricular rate      
≤50, hydrops and impaired left ventricular function (LVF) at diagnosis. The presence of  
≥1 RF was associated with a 10-fold increase in mortality before birth and a 6-fold 
increase in the neonatal period, independent of treatment. 
 
In paper III, the effects of prenatal exposure to maternal autoantibodies on heart function 
and conduction properties were investigated in a cross-sectional follow-up of pre-school 
children who did not develop fetal complete heart block. Sixteen patients who developed 
AV time interval prolongation in utero (group A) were compared with 41 who did not 
(group B). Ten percent (6/57) exposed to maternal autoantibodies in fetal life had 
developed first- degree AVB at follow-up, in spite of a normal ECG at birth or at 1 month 
of age. All 6 had prolonged AV-time intervals in utero. LVF in terms of M-mode, was 
normal in all patients, but myocardial performance index was slightly higher in group A. 
 
In paper IV, the outcome of young patients with CAVB and PM was studied 
retrospectively in a national cohort of 127 patients. Survival rate after 9 years of PM 
treatment was 96% and 8% developed LV dysfunction. There was a gender difference in 
cardiac status prior to PM but not at FU. Exposure to antibodies did not change the 
outcome significantly, but diagnosis <1 month of age and LV dysfunction before PM 
were associated with a poor outcome.   
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1 INTRODUCTION 
Congenital heart block (CHB), or congenital atrioventricular block (AVB) is a disease 
which in the absolute majority of patients develops after exposure in utero to maternal 
autoantibodies (SSA/Ro-SSB/La) passing the placenta to the fetus during the second 
trimester. The mothers of these children often, but not always, have a connective tissue 
disease like Sjögren’s syndrome or Systemic Lupus Erythematosus.   
 
CHB is a rare disease with a considerable mortality, especially in fetal life and the 
neonatal period. Practically all children surviving the neonatal period will eventually 
need to have a pacemaker implanted. This is a lifesaving therapy but not without 
problems for the child. When complete CHB has developed it is usually resistant to 
treatment and therefore current strategies aim at intervening before or at the onset of 
disease. The time span from onset of disease until development of the apparently 
irreversible complete heart block is sometimes short. The recognition and diagnostics 
of intermediate disease stages (first- or second-degree AVB) could therefore be 
lifesaving. On the other hand, diagnostics need to be able to distinguish these 
conditions from benign ones, avoiding unnecessary and potentially harmful treatment. 
Not all exposed fetuses develop the disease; with some showing only transitory 
conduction abnormalities in fetal life, normalizing at birth. These children are 
considered as having no risk for later disease progress, even if studies confirming this 
hypothesis are largely lacking.   
 
This thesis encompasses four aspects of the disease where, in my opinion, a knowledge 
gap in one form or another was present; diagnostics, pathogenesis, treatment and 
prognosis. We aimed to evaluate the diagnostic aspects in a regional cohort of fetal 
bradycardia focusing on the accuracy of differential diagnostics. The pathogenesis in 
clinical expression was studied in a similar cohort, focusing on the outcome of 
previously antibody exposed pre-school children who never developed complete CHB, 
in order to see if heart function and conduction properties were still normal at follow-
up. The treatment aspect was studied in the context of a multinational, multicenter 
format looking at the outcome of fetuses with second- or third- degree AVB with 
respect to treatment or non-treatment with transplacental fluorinated steroids. Possible 
risk factors associated with a poor outcome were identified. Finally, the outcome or 
prognosis of pacemaker treated patients with CHB was studied in a national cohort of 
young patients with antibody associated heart block and compared with those with 
heart block due to other reasons.   
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2 BACKGROUND 
 
2.1 HISTORICAL REMARKS 
In 1901, Morquio1 described the first case of a presumed congenital complete heart 
block (CHB) in the absence of major structural heart disease. The case was reported in 
the context of a familial condition with a permanently slow pulse, repeated attacks of 
syncope and sudden death. The first known case where ECG was included to beyond 
any doubt confirm the diagnosis of a CHB, was published in 1908 by van den Heuvel2.  
In the following years only sporadic reports of new cases appeared. The first initiative 
to an original study was taken within the European Association of Pediatric 
Cardiologists in 1964 and a preliminary report on 244 cases was published in 19673. 
This study was later extended and “merged” with a North American study, forming the 
basis for the now classic study by Michaelsson et al4, describing the natural history of 
this disease. 
 
2.2 DEFINITIONS AND CLASSIFICATION 
Although a congenital heart block (CHB) may initially appear as first- or second-degree 
atrioventricular block (AVB), it is often generally understood and synonymously 
described as a (1) congenital complete heart block (CCHB), (2) congenital complete 
atrioventricular block (CAVB), or (3) third-degree AVB. For readability reasons, this is 
the definition intended whenever the term congenital heart block (CHB) is used in the 
context of this thesis; unless otherwise specified. 
 
Complete AVB implies complete absence of conduction from atrium to ventricle in the 
presence of normal atrial activation and a slower dissociated ventricular rhythm with 
regular QRS-complexes5. 
 
Until around a decade ago, there was some confusion regarding how to define 
congenital complete AVB in terms of its temporal limitation, but in accordance with the 
proposal by Brucato and Rosenthal6, 7 in 2003, the now universally accepted definition 
is: “an AVB is defined as congenital if it is diagnosed in utero, at birth or within the 
neonatal period (0-27 days after birth)”. A CHB can be associated with structural heart 
disease, but in this context, CHB is synonymous with isolated CHB, i.e. in absence of 
any structural heart disease associated with the heart block. 
 
2.3 INCIDENCE 
The measures of incidence in rare diseases are often inaccurate, and this is most likely 
the case also for CHB. Several studies have provided numbers of incidence measures 
but if one looks closer at the calculations behind these figures they are often based on 
approximate data. Beginning with the incidence cited in the absolute majority of the 
articles concerning CHB, Michaëlsson et al where one of the calculations were made 
by referring to a study in which 27 cases of CHB were found among 3,000 cases with 
congenital heart disease. Assuming an incidence of congenital heart defects of 1/100 
live-born infants, an incidence of 1/15,000 was estimated. In the same paper referral 
was made to incidence calculations by another group, of around 1/22,000 (3 CHB in 
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67,000 deliveries in a Boston cohort from 1936 to 1962), and finally the authors 
concluded that taking these figures together with “various centers participating in this 
study indicate an average figure around 1 CHB per 20,000 live-born infants”. These 
incidence calculations from the early 1970s gave a first approximate number of the 
incidence of CHB, including those with structural heart disease. They were however 
not the results of estimations in a national cohort or similar.  
   
So which is the “true” incidence for isolated CHB? A reasonable approximation using 
the best data available so far, is probably to use the calculated “average” incidence of 
1/20,000, assuming that about 50-70 % of live-born children with CHB are isolated 
CHB. This would give an approximate incidence of isolated CHB of 1/30,000-40,000 
live-born. Julkunen et al8 had a different result in a Finnish study, where their estimate 
in the Finnish population was 1/17,000 (1:14,000-1:21,000), and even 1:11,000 
(1:8,000-1:17,000) in the 1990s. They did, however, include CAVB patients diagnosed 
up to 5 years of age in their figures. The strength of their study was that calculations 
were based on data from a national cohort. The authors speculate that the reasons 
behind the increased incidence could be that an increasing number of women with 
connective tissue disease manage to get pregnant due to improved treatment of their 
disease or that fetal treatment with IVIG, steroids, or plasmapheresis has increased 
survival in the group of CHB in recent years. There are to date no studies that can 
confirm such a hypothesis. 
 
 
2.4 CARDIAC CONDUCTION SYSTEM 
Embryology 
Some basic knowledge of the development of the heart and the conduction system is 
indispensable in order to understand the arising pathologies in connection with the 
disease progress of congenital heart block. An attempt at a brief summary will follow 
below.  
 
The development of the human heart starts around day 19, through the formation of the 
primary heart tube. In this early undifferentiated state, its walls consist of a primary 
myocardium already capable of slow conduction, slow contraction and spontaneous 
depolarization9. With the subsequent formation of the chamber myocardium, the 
conduction gets more rapid and it is already possible to record a relatively normal ECG, 
including a period of AV delay10. Within the primary heart tube a remodeling takes 
place, allowing for a separation of the atria and ventricles as well as the left- and right 
ventricular outflow tracts.  
 
At around week 7 of the development of the human fetus a gradual separation of the 
atria and ventricles begins at the AV canal, forming an insulating layer of connective 
tissue: the annulus fibrosus11. The process is thought to be completed at around week 
12 of gestation12. Animal studies have demonstrated the presence of multiple 
myocardial AV connections even in late stages of the development of the heart11. A 
subsequent immunohistochemical study of fetal and neonatal sectioned hearts from 4 to 
36 weeks of gestation, confirmed that the isolation of the AV junction is a gradual 
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process  completing at between 10 and 20 weeks, but with thin persisting AV muscular 
connections up to 20 weeks13.  
 
The sinus node (SN) is recognizable already at 5 weeks of gestation, initially as a U-
shaped structure comprising the definitive right sided SN and a transitory, temporary 
left sided SN; where the latter appears earlier in development and is larger than the 
right sided SN 14, 15 but disappear in the course of  normal maturation and development 
of the heart. In early development, a “double” AV node with a posterior and anterior 
node is present, later fusing to a single AVN primordium16, 17.The posterior node 
subsequently connects to the His bundle, eventually forming the definitive AVN18. The 
final maturation of the AVN is thought to be completed during the first year of life19. 
 
Function of the cardiac conduction system 
The cardiac conduction system (CCS) consists of the sinus node (SN), the 
atrioventricular (AV) conduction axis (comprising the AV node), the left and right 
bundle branches and the Purkinje network. The entire system is made of highly 
specialized cells with the unique properties of electrical conduction. The SN generates 
impulses, rapidly spread over both atria. The atria and ventricles are electrically 
isolated from each other by a stratum of connective tissue, which is penetrated by the 
AV conduction axis along which the impulse from the atrium is propagated, 
constituting the only atrioventricular connection of the normal heart.  
 
The function of the SN is distinctly different from the working myocardium in that the 
action potential (AP) has a slow upstroke because it is not generated by an increased 
Na-current into the cell but instead by smaller and slower T- and L- type Ca2+ -
currents10. Interestingly, in a study by Qu et al20 on human fetal heart cells, the alpha-
1D L-type (Cav 1.3) calcium channel, considered a key player in the SN function and 
the generation of the diastolic depolarization, was demonstrated to be blocked by CHB 
Ig G. This finding could support clinical observations of sinus bradycardia appearing in 
antibody exposed fetuses and children. 
 
The normal and fastest route for the AP from the SN to reach the AVN is through a 
pathway along the interatrial septum10. It is located at what is known as the base of the 
triangle of Koch, which is in turn located at the base of the atrial septum. The main 
function of the AV node is basically to conduct the AP from the atria to the ventricles, 
decreasing the velocity and by doing so, allowing for the atrial systole to take place 
before the ventricular systole, enabling an adequate filling of the ventricles. Its capacity 
of reducing AP frequency to the ventricle protects the heart from very fast rhythms, 
while its capacity to act as a secondary pacemaker has a savior function in case of sinus 
node dysfunction or a complete heart block10.  There is a vast difference in the 
morphology of APs within the AVN, believed to reflect the difference in ionic currents 
and ion channel expression21. As in the SN, Ca -currents rather than Na-currents are 
thought to be responsible for the upstroke of the AP and just like in the SN, the subunit 
of the L-type Cav1.3 is upregulated in the AVN
22. This is interesting as one of the 
hypothesis of the cross reacting effect of Ro/SSA AB suggests an interaction with this 
channel. Another important function of the AVN is the ability for automaticity of the so 
called junctional P cells which hence not only act as conductors of the AP from the SN, 
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but are also capable of “producing” an effective escape rhythm in case of failure of the 
SN or appearance of complete AVB19.   
 
Disease progress 
The exact mechanisms of the progressive development from normal cardiac conduction 
to end stage CHB are not clear. The assumption is a gradual development through all 
intermediate steps, possibly over days or weeks in some cases. The leading hypothesis 
(see Pathogenesis) is an interaction between SSA/Ro autoantibodies and maybe the 
above described Ca-channels-Cav1.3 and Cav3.1-shown to be important for the 
automaticity of AVN cells. Another important player is the HCN-channel, shown to 
cause SB and AVB in in a knock-out mouse model23. How these ion channels are 
influenced on a molecular level at the different stages of AVB is not known. The 
different stages of AVB are usually categorized in first- second- and third-degree AVB. 
 
First-degree atrioventricular block 
In first degree atrioventricular block (AVB), the impulse or action potential (AP) 
generated in the sinus node (SN) and travelling down to the AV node, is delayed 
causing a prolonged PR interval on ECG. 
Second-degree atrioventricular block 
In second degree AVB (AVB II), at least one (but not all) of the impulses generated in 
the SN is not conducted to the ventricles. There are mainly two types of AVB II; 
Mobitz type 1 where, after a progressive delay of the impulse conduction, one impulse 
is not conducted and Mobitz type 2 where the impulses are intermittently not 
conducted, without a previous prolongation of the delay in the AV node. Mobitz type 2 
AVB II is considered a more advanced AVB and less stable in its form. There is often a 
fixed number of non-conducted impulses for every normally conducted impulse to the 
ventricle per cycle.  
Third-degree atrioventricular block  
In third degree or complete AVB there is a complete dissociation between the rhythm 
in the atria and the ventricles, with a slower ventricular rhythm, regular QRS-
complexes and resulting bradycardia. 
 
 
2.5 ETIOLOGY 
Congenital heart block as a part of Neonatal lupus syndrome  
Neonatal lupus syndrome (NL) is an uncommon autoimmune disease and represents a 
model of passively acquired autoimmunity24. The serum of the pregnant woman 
contains maternal autoantibodies to soluble, intracellular ribonucleoproteins 48kD 
SSB/La, 52 kD SSA/Ro or 60 kD SSA/Ro25, 26. Half of the mothers are asymptomatic 
carriers of these antibodies, whereas the other half have Sjögren’s Syndrome, Systemic 
Lupus Erythematosus (SLE) or Mixed Connective Tissue Disease. In the newborn child 
a skin rash is often present, but the most serious manifestation is congenital heart block.  
 
Congenital heart block is strongly associated with exposure to these maternal 
autoantibodies which are present in 85-90% of the mothers to children with CHB 
diagnosed in the perinatal period. Even if it is now common to categorize prenatally 
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diagnosed CHB and those diagnosed in the first month after birth in the same group, it 
seems that nature does not comply with this categorical definition, as cases diagnosed 
in fetal life have a higher percentage of exposure to maternal autoantibodies, around 
95-98%27, 28.  
 
Until the beginning of 1970s, the etiology and pathogenesis of CHB was largely 
unknown and thought to be associated with infectious agents or unknown hereditary 
factors. Following single observations of offspring with CHB to mothers with 
connective tissue disease, the first systematic reports showing this association appeared 
in 197729, 30 and 197931. In 1983, Scott et al32 showed that > 80% of the mothers to 
children with CHB had antibodies to a soluble tissue ribonucleoprotein antigen called 
Ro (SSA); a finding that has been confirmed repeatedly in later studies. 
 
Non immunologic congenital heart block 
In about 5-15% of patients, the heart block has developed without exposure to maternal 
autoantibodies. In the clinical context of a negative test with respect to presence of 
maternal autoantibodies, the preexistence of a clearly recognizable underlying disease 
is rare.  
 
Association with extracardiac disease or cardiomyopathies 
Neuromuscular disorders are sometimes referred to be connected with CHB, but they 
seem rather to develop and progress in childhood, being extremely rare at birth 33. In a 
similar way, certain subtypes of familial dilated cardiomyopathies are associated with 
various degrees of AVB, but practically always appearing in childhood or later34, 35.  
 
Infectious agents and congenital heart block 
Infectious agents - sometimes present at the time of diagnosis of AVB in childhood - 
could theoretically cause myocarditis and AVB through maternal-fetal transfer of viral 
antigens inducing conduction disorders. Reviewing the literature there are, however, 
only single cases diagnosed before one month of age36 and no published cases with a 
CHB, and myocarditis verified by heart biopsy, in the absence of maternal 
autoantibodies. One could also mention the fact that certain viral antigens have been 
suggested to in some way facilitate the development of CHB in antibody-exposed 
patients, there is however no evidence supporting that hypothesis.  
 
Hereditary components  
A recent multicenter study showed that parental conduction disease was present in 
about half of the cases of non-immune isolated AV block presenting in utero, in the 
neonatal period or in childhood 37, 38. Eighteen percent of the cases were CHB. The 
cohort included patients from 13 different centers, making prevalence and incidence 
difficult to estimate, but this highly interesting finding suggests that the so far 
unexplained remainder of CHB not associated with maternal autoantibodies, to a 
substantial extent could have a hereditary/genetic background. 
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2.6 PATHOGENESIS 
From association to explanation? 
 
Ever since the first reports and observations in the 1970s and -80s and the apparently 
convincing link between SSA/Ro exposure and development of AVB, there has been 
continuous work to form hypotheses and explain underlying mechanisms in the 
pathogenesis. To date, it has not been able to explain why only 1-2% of children 
exposed to SSA/Ro autoantibodies develop CHB 39 40. However, the fact that the 
recurrence rate in subsequent pregnancies is 12-20%41 41-44 indicates that other factors - 
maternal, fetal or both - play a role in the evolution of CHB. 
 
Passive immunization through anti-SSA/Ro antibodies 
At the outset of the research in this field, a bystander effect had to be excluded and a 
possible causal effect of the antibodies investigated, for which reason animal models 
were developed to study the role of the SSA/Ro-SSB/La antibodies in the pathogenesis. 
A passive model of CHB was developed where pregnant mice were injected with 
SSA/Ro-SSB/La antibodies from mothers of children with CHB. The offspring 
developed first-degree AVB to a high extent as well as sinus bradycardia but none 
developed CHB45. Several active mouse models (female mice and rabbits immunized 
with Ro 52, Ro60 and La 48 antigens) could subsequently show a range of conduction 
abnormalities developing, including CHB in a few cases 46-48. The acute effect of anti-
Ro/La antibodies was studied in Langendorff perfused mouse and human fetal hearts 
showing a progressive development from sinus bradycardia to first-, second- and finally 
third-degree AVB47, 49-51. These animal- and in vitro -models thus gave further evidence 
for the central role of SSA/Ro-SSB/La autoantibodies in the pathogenesis. 
 
The presence of immunoglobulin deposits in the heart of human fetuses who died due 
to CHB, for the first time linked maternal SSA/Ro autoantibodies to the development 
of CHB on a cellular/molecular level. Deposition of immunoglobulin, fibrosis and 
calcification, not only at the AV node but throughout the myocardium, suggest a link to 
tissue damage, as seen in the clinical picture of CHB52, 53. 
 
One question that has still not been completely answered is how the Ro/La antigen 
exert their effect as they are intracellular proteins, unable to penetrate the cell 
membrane of the cardiomyocyte. I will below briefly mention some of the current 
hypotheses and research results that attempt to constitute an explanatory link between 
the molecular- and clinical observation level.  
 
Apoptosis-Inflammation-Fibrosis hypothesis 
It has been proposed that translocation of the intracellular SSA/Ro antigen to the cell 
surface, making it accessible to interaction and binding with antigens, becomes possible 
through apoptosis of the cardiomyocytes46. A fairly recent study has shown that it is 
mainly the Ro60 Ag component, and to a lesser extent, in late apoptosis, the La 
component, that are expressed on the cell surface, not Ro5254. But if  apoptosis is a 
normal phenomenon in the fetal heart, why should it provoke a cascade of 
inflammation and fibrosis55?  
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One hypothesis is that anti Ro60 antibodies bind to apoptotic cardiac cells, thereby 
blocking the normal non-inflammatory pathway, diverting instead to an inflammatory 
pathway and subsequent ingestion by macrophages leading to an exaggerated 
apoptosis. This process is further suggested to contribute to the transdifferentiation of 
cardiac fibroblasts to a scarring phenotype; thus providing an explanation for the 
“endstage” of CHB with fibrosis of the AV-node.56-58 
.  
Furthermore, impaired clearance of apoptotic cardiomyocytes , resulting in 
accumulation of apoptotic cells, promoting inflammation and formation of subsequent 
scarring, are thought to play a role in the process59. This hypothesis still does not 
explain the role of Ro52, showed to be more common than Ro60 in children with 
CHB60, so it has been suggested that Ro52 acts in a later phase of the process, binding 
to the necrotic cardiomyocytes and promoting a process towards calcification and 
fibrosis.  
 
Research focusing on the role of anti-Ro52 antibodies, has shown that levels of 
maternal antibodies to the amino acid p200 of the Ro52 protein were significantly 
higher in mothers of children with CHB compared with in mothers of those who did not 
develop heart block61. This finding has been further supported in that high levels of 
p200 were seen to be correlated with AV time interval prolongation in exposed fetuses, 
in a study by Salomonsson et al48. The same group reported that p200 antibodies bind 
to the cell surface and dysregulate calcium homeostasis in cardiomyocytes, leading to 
cell death; shown in cardiomyocyte cultures from neonatal rat. The above studies have 
led to formulation of the hypothesis that anti-Ro52 antibodies mediate their effect on 
the fetal heart by cross-reacting whith another molecule on the cell surface, possibly 
involved in the regulatory system of the cardiac excitation-contraction system55. The so 
called L- and T-type calcium channels have been suggested to be involved in this 
system, and contain subunits involved in cardiac contractility as well as in AV-node 
conduction and sinus node activity.62, 63. 
 
The results presented thus far led the group of Wahren-Herlenius and other leading 
researchers in the field64 to launch a hypothesis or explanatory model 55, briefly 
recapitulated below. 
 
A cross-reaction of passively transferred anti Ro52-antibodies with one or several 
molecules, possibly involving the aforementioned L-type Ca-channels, induces 
disturbance of the calcium homeostasis, calcium overload and apoptosis. La- and anti-
Ro60 autoantibodies may then bind to the apoptotic cells. This could lead to conduction 
impairment at the AV node affecting the cardiac excitation-contractility process on the 
cell surface of the cardiac myocyte in early pregnancy; hypothetically corresponding to 
the AV time interval prolongation seen in anti Ro antibody exposed fetuses. It could 
also explain the signs of impaired cardiac performance seen in a study of antibody-
exposed fetuses without subsequent development of CHB65. Depending on the presence 
of certain fetal susceptibility genes, the inflammation is then suggested to take either of 
two directions: resolving or becoming chronic. The latter pathway would then lead to 
an exaggerated inflammatory response with increased cell apoptosis and initiation if the 
inflammatory cascade, eventually leading to irreversible damage with fibrosis and 
calcification of the AV-node and as a consequence: complete heart block.  
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This model of pathogenesis, although providing convincing evidence regarding the 
mechanisms, takes us back to where we started: Why do only 1-2% of the antibody 
exposed fetuses develop heart block? And why is there a recurrence rate of 12-20% in 
already affected families? Furthermore, with the assumption that CHB is a progressive 
disease: why do some fetuses only develop discrete signs of disease, in form of 
transitory first-degree AVB whereas others die of heart failure already in fetal life? The 
level of antibodies have been suggested to play a role in disease expression but there 
has not been convincing evidence supporting this hypothesis, apart from a recent study 
by Jaeggi et al where cardiac complications appeared only in the presence of moderate 
or high maternal titers of anti-Ro levels, regardless of the anti-La antibody titers66.  
 
Other factors have been explored and suggested to play a role in the process of disease 
expression: 
 
Genetic contributors 
A study looking at genetic polymorphisms in two different genes, encoding TNF-alpha 
and TGF-beta, indicated that the genotype of the fetus could be of importance for the 
development of CHB67. In a more recent study, focusing on variation at the Major 
Histocompatibility Complex (MHC), it was shown in a rodent model that maternal 
MHC determine both the maternal ability to form pathogenic antibodies and the fetal 
susceptibility to develop CHB68. Finally, in a study by Meisgen69 et al, HLA-DRB1*04 
and HLA-Cw*05 alleles were identified as novel fetal HLA allele variants associated 
with susceptibility to CHB in response to Ro/SSA autoantibody exposure, whereas 
DRB1*13 and Cw*06 seemed to be protective alleles. A paternal contribution to 
susceptibility was also shown for the first time. 
 
Environmental factors  
Fetal as well as maternal factors possibly associated with the development of CHB 
were studied in a Swedish nationwide cohort44. Older maternal age was shown to be 
associated with CHB development, as well as pregnancies with gestational weeks 18-
24 occurring in January to March, giving rise to a hypothesis connected with a decrease 
in light exposure, possibly leading to lowered vitamin D levels.  
 
To summarize, there has been an incredible development and increased insight in the 
pathogenesis of this disease over the last decades, but nevertheless important parts of 
this puzzle are missing in order for us to understand the enormous spectrum of disease 
expression as well as the low penetrance of the disease.  
 
 
2.7 DISEASE EXPRESSION 
CHB as a part of Neonatal lupus syndrome 
Transfer of antibodies is thought to begin as early as 11 weeks of gestation but the heart 
block is usually diagnosed in week 18-24, a period often referred to as the susceptibility 
period, when maximum antibody passage is thought to take place70. The earliest 
observation of a CHB is around week 16 of gestation71. The heart block is thought to 
evolve progressively from normal sinus rhythm to first- second- and eventually a third-
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degree heart block. This is a reasonable assumption as there are now several published 
cases where these different stages have been observed in a single patient. There is, 
however, no timetable for when these events occur and the time intervals from the 
earliest stages of disease onset to development of CHB seem to vary considerably 
between individuals. In some cases a complete AVB does not develop until after 
birth72.  
 
With improved diagnostic techniques and surveillance of pregnancies at risk, first- and 
second-degree AVB are increasingly often diagnosed already in fetal life. The total 
impact of the antibody exposure is not dependent exclusively on the development of 
CHB, but also on the degree of myocardial affection with a possible myo- and/or 
pericarditis, hydrops or development of endocardial fibroelastosis (EFE). The latter is a 
feared consequence of antibody exposure, often leading to fetal or early neonatal 
death29, 73-75. There are even cases with EFE without affection of the conduction system 
with a poor outcome, suggesting that CHB and EFE are two different but associated 
manifestations of neonatal lupus. 76, 77. The clinical expression of antibody associated 
CHB is hence highly variable, from cases of early fetal demise in heart failure to others 
with a stable ventricular HR, a normal left ventricular function and excellent long term 
prognosis. The reasons for this spectrum of disease expression are to date unknown.  
 
If the outcome at birth is a normal left ventricular function and a stable nodal escape 
rhythm with a sufficiently high ventricular heart rate without sudden pauses, a PM 
implantation is often not immediately necessary. The absolute majority will, however, 
eventually receive a PM. At the age of 1 year about two thirds of the CHB patients in 
the American neonatal lupus registry had a PM implanted39. Neonatal extracardiac 
manifestations as a result of the antibody exposure include skin rash, elevated liver 
enzymes, and cytopenia78-81. In contrast to the cardiac manifestations, they resolve 
spontaneously as the maternal autoantibodies are cleared from the maternal circulation. 
Curiously, it seems to be more common that girls are affected by skin rash than boys82  
 
Even if sinus bradycardia (SB) has occasionally been reported in antibody exposed 
children with CHB83, 84, other studies suggest that the atrial heart rate is normal in the 
majority of patients with CHB85 . One of the studies reported on a range of disease 
expression connected with SB, from asymptomatic cases without CHB to severe heart 
failure with EFE86. In a cohort of antibody exposed individuals, 4% were found to have 
SB40, whereas no difference in HR was seen compared with unexposed individuals in 
another cohort87.  This has been proposed to be a result of the effect of the maternal 
autoantibodies on the sinus node (SN), but the mechanism has not yet been elucidated. 
Recent hypotheses, however, suggest an interaction with calcium channels at the SN88. 
Even if there may be an interaction at a molecular/cellular level, the clinical impact 
seems to be very limited with the absolute majority of CHB patients having a 
sufficiently normal SN function.  
 
At least one study has reported on QT interval prolongation in patients exposed to 
SSA/Ro- SSB/La autoantibodies who did not develop CHB89, but the findings could 
not be confirmed in a subsequent study where exposed children were compared with 
unexposed without showing any difference in QTc interval87. QTc prolongation in 
CHB patients has been reported in two studies from the same group90, 91 and was 
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considered to be a risk factor of a poor outcome and the implantation of a pacemaker 
was recommended. In the latest European guidelines for PM implantation QT interval 
prolongation is not mentioned as an indication for pacing92. 
 
 
2.8 DIAGNOSTICS OF FETAL HEART BLOCK 
Whereas postnatal diagnoses of incomplete and complete AVB are uncomplicated and 
very straightforward, diagnostics of AVB in fetal life can be much more complicated, 
especially when the degree of AVB is oscillating. Just like on a postnatal ECG, fetal 
rhythm diagnostics is based on the recognition and chronology of atrial and ventricular 
depolarization. For obvious reasons, a regular ECG of the fetus is not available and 
diagnostics therefore have to rely on other techniques.  
 
Fetal ECG 
The first published attempt of monitoring fetal heart rhythm was undertaken more than 
a century ago using a so called string galvanometer electrocardiograph, obtaining 
records by placing one lead on the abdomen and one in the vagina of a nine months 
pregnant woman93. The recording showed low voltage deflections superimposed on the 
maternal ECG. Further technical development was achieved by various researchers in 
the decades following94-96. In spite of development of more refined techniques with 
low-noise measurements and digitized systems in the last decade, the initial problem 
with a relatively low signal to noise ratio (SNR) has not yet been completely solved, at 
least not to the point where various arrhythmic substrates can be reliably 
differentiated97. More recent studies have shown that in about 25-40 % of the cases, not 
all atrial depolarization (P-wave) are detected98, 99, although single groups have 
compared Echo Doppler-derived mechanical intervals with fetal ECG, claiming the 
latter to be superior in differentiating normal from prolonged PR intervals100. The lack 
of new reports or studies in the last years, underlines the fact that this method has still 
not gained ground in the clinical practice, although it has potential. 
 
Magnetocardiography 
Magnetocardiography (MCG) is a non- invasive technique for recording magnetic 
fields generated in the heart. By using high sensitivity sensors, the weak signals emitted 
in the fetal heart are amplified, resulting in an ECG of a quality much superior to a fetal 
ECG, providing information on all important elements of the electrical cardiac cycle, 
and enabling measurements of different time intervals. The method has been and is 
still, an important source of information and has given new insights in fetal 
electrophysiology101, 102. Unfortunately, the method has considerable disadvantages in 
that the examination is time consuming, takes place in a magnetically shielded room 
and is expensive; all contributing to the fact that very few hospitals around the world 
are equipped with a fetal MCG. 
 
Fetal echocardiography and Doppler techniques 
Given the various drawbacks of the above methods as simple and reproducible tools in 
the diagnostics of fetal arrhythmias, echocardiography with M-mode and Doppler 
techniques remain the modalities of choice for most fetal cardiologists and obstetricians 
in the diagnostics of arrhythmia in clinical practice. Whichever method used (M-mode, 
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Doppler flow techniques or Tissue Doppler imaging (TDI)), it is not the cardiac 
electrical activity per se that can be measured, but its mechanical consequences. This 
must be kept in mind, even though it in most cases, and using the appropriate method, 
is sufficient to reveal the underlying arrhythmia.     
 
Classification of the bradyarrhythmic substrate 
The M-mode approach, the first method used in fetal arrhythmia diagnostics, is based 
on the simultaneous recording of atrial- and ventricular wall movements, reflecting 
atrial and ventricular depolarization. The first reports from the early 1980s showed that 
many underlying arrhythmic substrates could be diagnosed correctly by using M-mode, 
though the precision or accuracy of the method was not evaluated103, 104. A complete 
heart block can normally be diagnosed with a high precision, whereas measurements of 
cardiac time intervals are usually impracticable due to the sometimes unclear onset and 
peak of the atrial and ventricular contractions.  
 
Doppler flow techniques use the principle of detection of the initial phase of blood flow 
velocity alterations within the vessels as a mechanical result of previous cardiac 
electrical activity. The benefits of this method were shown by Strasburger et al105 in a 
report from 1986, comparing M-mode and Pulsed Doppler echo. Several studies have 
shown the superiority of the latter method compared with M-mode in measuring the 
mechanically derived AV intervals, corresponding to the PR intervals on ECG106-108.   
 
Over the years, techniques using different Doppler methods and approaches have 
developed based on simultaneous recordings from (1) Mitral valve and left ventricular 
aortic outflow (MV-Ao), (2) Superior vena cava and ascending aorta (SVC- Ao) and 
(3) a pulmonary vein and a pulmonary artery.  The methods are complementary and 
used for different purposes. In addition to this, they are all angle dependent and the 
position of the fetus at the time of examination will therefore influence on the choice of 
method.  Recordings from the pulmonary trunk and ductus venosus seem to be less 
used, even though the latter method was described more than two decades ago109. 
However, these methods have been among the standard methods used at our institution 
for many years, for reasons that will be further elucidated below. I will briefly describe 
the usefulness and disadvantages of the mentioned methods in the diagnostics of fetal 
bradyarrhythmia, including incomplete AVB.  
 
AV- interval measurements and diagnostics of first-degree AVB. 
The probably most frequently used methods of measuring Doppler derived time 
intervals are the MV-Ao and VCS-Ao methods; especially the former, as it is usually 
fairly easy from a technical point of view to obtain good quality recordings (see figure 
2.8.1). AV time interval measurements have, as mentioned above, been used for many 
years as a substitute for the postnatal PR interval to describe and evaluate conduction 
properties in the fetus. Reference values are established and several studies have 
validated the method.  
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Figure 2.8.1. Doppler recording from the left ventricular inflow (mitralis) and left ventricular 
outflow (aorta). The hemodynamic results of the atrial contractions (A wave) are marked with 
a. The Atrioventricular (AV) time interval is measured from the intersection of the E- and A 
waves to the beginning of the ejection wave of the aortic outflow.  
 
How good or relevant is the method in predicting PR interval prolongation after birth? 
It is not as easy as it may seem to answer that question. Theoretically, AV interval 
prolongation as a result of intrauterine exposure to SSA/Ro autoantibodies could be 
transient, thus normalizing at birth and “failing” to prove its predictive value. In fact, in 
a study by Sonesson et al110 one third (8/24) of antibody-exposed fetuses developed AV 
time prolongation, exceeding +2 z-score of published reference intervals107 in at least 
two consecutive examinations, persisting at birth in 4/8. This study not only supported 
the hypothesis of CHB as a progressive disease, but also raised questions regarding the 
normal reference intervals and predictive value, challenged by the PRIDE-study where 
a value of 3 z-scores above the mean was used as a cut-off, and hence reporting a 
smaller percentage of individuals with prolonged AV interval111. If fetal MCG is to be 
used as the gold standard, a prospective comparison between fMCG and Doppler- 
derived AV time interval measurements would probably be valuable. However, in the 
view of many fetal cardiologists, these Doppler methods are good alternatives to a fetal 
ECG or fMCG and can be used in the surveillance of conduction properties in this 
patient group. As a matter of fact, there is an additional value in that ICT interval 
measurements could reveal a prolongation, possibly representing early signs of cardiac 
involvement in exposed patients, see below.  
 AV time intervals are consistently longer than PR intervals on postnatal ECG112 as 
well as in a comparison with signal averaged fetal ECG98. The explanation for this is 
that the AV interval includes the early systolic time interval (ICT; isovolumetric 
contraction) that precedes the opening of the aortic valve. Therefore, the proposal has 
been made, to exclude the ICT interval from the AV interval measurements but as was 
shown in a study by Bergman et al65 this could lead to a failure in registering the 
prolonged ICT that has been seen in SSA/Ro antibody exposed fetuses, hypothesized to 
be a sign of decreased cardiac performance.  
 
Diagnostics of second – and third degree AVB 
In complete AVB, there is a constant dissociation between atrial and ventricular 
depolarization. Unless the atrial rhythm happens to be exactly twice that of the 
ventricular escape rhythm at the time of examination, thus mimicking a 2:1 second-
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degree AVB, the diagnosis can usually be made, irrespective of the chosen method, 
even with M-mode. A second-degree AVB with a varying degree of block, behaving in 
a Mobitz type I or II manner, or even oscillating between the two, makes diagnostics 
more complicated. Occasionally, even a predominantly complete AVB can vary 
between a second- and third-degree block. In these more complex situations 
simultaneous recordings of venous and arterial profiles can increase the possibilities of 
a correct diagnosis.113-115. Many fetal cardiologists would still use MV-Ao Doppler to 
assess the arrhythmia, probably because it is more easily accessible, but as can be seen 
in an example in fig 2.8.2 below, the events occurring in the atrium are less clearly 
visible even in complete AVB, compared with the SVC-Ao (figure 2.8.3) or in 
recordings from the pulmonary trunk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8.2. A Doppler recording from the left ventricular in- and outflow tract (MV-Ao) 
showing a complete heart block and atrioventricular dissociation with the superiorly directed 
slower ventricular outflow and the faster, inferiorly directed inflow, with the A waves marked 
(a), sometimes not clearly visible during ventricular systole 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.8.3. Doppler recording from vena cava superior (above the baseline) and aorta (flow 
directed inferiorly) showing a complete heart block with a slower ventricular rhythm and the 
clearly visible atrial contractions (a) even during ventricular systole. 
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Why is it important to differentiate between second- and third-degree AVB? 
A third degree AVB is usually irreversible whereas single reports indicate that a second 
degree AVB can be reverted or at least prevented from progressing to a higher degree 
of AVB if treated with fluorinated steroids116-118. It appears that the window of 
treatment is narrow, making a fast and accurate diagnosis is of uttermost importance. 
 
Benign atrial bigeminies and second-degree AVB- a potential diagnostic dilemma? 
At our institution, we had occasionally observed difficulties in differentiating second-
degree AVB from mid gestational blocked atrial bigeminies (BB). These sustained BB, 
resulting in a temporary reduction of the ventricular heart rate, are well tolerated by the 
fetus, frequently resolve spontaneously and require no treatment115, 119, 120. For obvious 
reasons, high quality differential diagnostics are crucial in order to distinguish this 
benign condition from a potentially lethal condition that could possibly be prevented 
from evolving if treated in time.  
 
Recognizing that this diagnostic dilemma was experienced by others121, we decided to 
study the underlying mechanisms in fetal bradycardia  and to study the ability of Echo 
Doppler techniques in differentiating between them (Paper I).     
 
 
2.9 NATURAL COURSE 
Natural history of CHB- fetal and neonatal outcome 
If natural course is taken to mean that no interventions that could possibly alter the 
course of the disease have been undertaken, none of the studies below describe the 
natural course. Some of the patients were treated with transplacental fluorinated 
steroids or were given a PM immediately after birth. Even in the study by Michaëlsson 
et al4, a few of the more diseased patients were paced just after birth.   
 
One of the first groups to describe the outcome in CHB detected prenatally was 
Schmidt et al who found that 85% of the cases with isolated CHB survived the neonatal 
period122. Another single-center study reported on the outcome of 36 fetuses with 1/3 
dying in fetal life or immediately after birth. Hydrops and low heart rates were 
associated with a poor outcome123. In a Finnish cohort of 91 patients where around 90% 
were diagnosed in fetal life, the perinatal mortality was surprisingly low at 7%124. 
Given the fact that patients diagnosed as far back as 1950 were included, there is a 
considerable risk of not having included some cases of intrauterine demise. Finally, in a 
study on fetal, neonatal and childhood diagnosis of complete AVB, 41% of those 
diagnosed in fetal life did not survive to 1 week of age. Taken this and other studies 
together, survival to 1 month in fetal CHB is around 60-90%.  Reasonable explanations 
to the variation in mortality rates are: (1) some of the most diseased patients not being 
included, (2) multicenter studies with unclear selection procedures, (3) studies spanning 
over several decades with changing treatment strategies including early pacemaker 
treatment.   
 
In the now classic publication by Michaëlsson et al from 1972, the natural history of 
congenital heart block -including cases with associated disease- was described 
extensively in an inimitable way; a great part of our knowledge comes from that single 
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publication. A few problems emerge, however, when we try to extrapolate and 
generalize the outcome on a larger population, especially regarding the fetal 
perspective. The study included patients born in the 1940s and onwards and for obvious 
reasons we have only limited knowledge of fetal outcome from the study. As the 
authors conclude, the fact that the average age at death was lower in those diagnosed in 
more recent years could be attributed to the fact that many children from the earlier 
period never had a chance to be diagnosed in the first place. With sampled cases from 
many centers all over Europe, and limited control over selection bias (patients with an 
early/fetal diagnosis and a poor outcome are more likely not to have been included), 
make the mortality figures less reliable.  
 
Another issue relates to the diagnosis. The study group was divided into those 
diagnosed < 1 week, < 1 year and < 15 years. In all, 122/418 patients were diagnosed in 
fetal life or at birth and would by the current definition correspond more closely to the 
group of “real” congenital heart block. The follow-up time is not explicitly mentioned, 
but half of the 122 patients had reached the age of 5 years by the end of the study. The 
mortality rate was 15% in those diagnosed at birth; all deaths occurring before the age 
of five. Four of the 42 patients diagnosed at  > 1 week but < 1 year of age died. Five of 
the 122 patients had a PM implanted and all died; 2 of 5 supposedly as a result of the 
implantation itself. 
 
Taking the results of these early studies together, they all confirm that most of the 
patients at risk of a poor outcome present in fetal life or at birth, whereas those who 
survive the neonatal period generally have a good outcome. There is little doubt that 
PM therapy has improved the outcome, both in those needing early pacing and in the 
apparently asymptomatic patients who nowadays will receive a PM, acknowledging the 
risk of sudden death even in this group90.  
 
 
2.10 TREATMENT 
2.10.1 Fetal treatment approaches 
We know that fetuses and neonates with congenital heart block have a considerable risk 
of a poor outcome with a high perinatal mortality. As a consequence, studies and 
evaluations of therapeutic interventions have been a high priority in the research 
community around CHB, possibly finding a curative or prophylactic treatment; or at 
least a treatment that could mitigate the effects and improve the outcome in terms of 
morbidity. Considering the widely adopted hypothesis of pathogenesis and disease 
progress, with inflammation as a possible intermediate step towards a definitive 
calcification and fibrosis of the conduction system, there is intrinsic logic to a therapy 
aiming at diminishing the consequences of inflammation and/or lowering the titers of 
the circulating maternal autoantibodies. Accordingly, many therapeutic attempts at 
reducing the degree of AVB in cases of fetal complete AVB, have been undertaken, 
above all transplacental treatment with fluorinated steroids (dexamethasone or 
betamethasone)116, 125-127 118, only partly inactivated or metabolized in the placenta. 
Another consequence of the inflammatory process following fetal exposure to maternal 
autoantibodies is the presence of hydrops or ascites/pleuropericardial effusions which 
has been reported to resolve after steroid treatment118, 128, 129. There are, however, no 
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randomized studies to support these observational reports. Treatment of EFE cases has 
also been tried with no apparent beneficial effect75, 86 
 
Other treatment strategies have also been explored. Plasmapheresis lowers the levels 
of SSA/Ro- and SSB/La levels in maternal blood130, and could thereby theoretically 
prevent or diminish the damage induced by the maternal autoantibodies in the fetus. 
This treatment has practically always been combined with steroids, making its 
individual contribution to possible treatment effects difficult to assess. There are reports 
of single cases in combination with steroids where treatment seemed to be of no benefit 
in cases of complete AVB but with a possible effect on myocarditis or pericarditis in 
some cases129, 131-133. Intravenous immunoglobulins (IVIG) are thought to exert their 
effect by inhibiting or reducing the transplacental passage of maternal autoantibodies, 
accelerate their clearance and reduce the inflammatory response in the fetus134-136. This 
hypothesis is supported by an animal study where IVIG treatment inhibited the transfer 
of maternal autoantibodies across the placenta in a murine model, according to the 
researchers most likely by blocking the Fc-receptors of the placenta137. Maternal 
betamimetic therapy has also been tried, with the objective to increase HR and 
survival to birth, with limited benefit in most reports84, 125, 138, 139. 
 
 
2.10.2 Fetal treatment based on indications 
2.10.2.1 Treatment to improve survival  
Transplacental steroid treatment has been proposed to improve the outcome of 
complete AVB, in terms of both morbidity and mortality. However, there are no trials 
on a larger scale supporting such a strategy, only a few smaller studies, of which only 
the one by Jaeggi et al125 showed a better survival in the steroid treated group than in 
the untreated historical “control group”. The unexpectedly low survival in the untreated 
group compared with that in other studies, combined with the fact that the study 
compares patients from two different eras, has not convinced the profession of fetal 
cardiologists that steroid treatment is beneficial. Accordingly, there is currently no 
consensus as to if the treatment is efficient or not and hence, therapy traditions seem to 
vary between centers around the world.  
 
2.10.2.2 Treatment to improve AV conduction 
When a complete AVB has evolved it is usually permanent and resistant to any form of 
intervention aiming at restoring normal cardiac conduction. There are sporadic reports 
of fetal interventions claiming to have restored normal conduction, but published cases 
with sound proof are to date lacking. Several reports combined single doses of IVIG 
with combination therapy with steroids, showing no effect on the heart block but 
resolution of myocarditis in a few cases140-142. All different therapeutic approaches have 
so far been shown to be inefficient in treating a complete AVB.  
 
There are reports of small series or single cases where incomplete AVB reverted to 1:1 
conduction or sinus rhythm within weeks after initiation of transplacental steroid 
treatment in some but not all fetuses113, 116-118, 143-147. In a small study of 3 patients with 
second-degree AVB and 3 with CAVB, a combination therapy consisting of IVIG, 
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plasmapheresis and fluorinated steroids throughout the pregnancy was attempted, with 
reversion to SR from second degree AVB in 2 cases, but no effect on the CAVB148. 
 
2.10.2.3 Treatment to prevent first-degree AVB to progress 
First degree AVB is known to be present in up to 30% of prospectively followed 
fetuses exposed to maternal autoantibodies110; the cut-off value for the upper normal 
limit deciding its incidence in larger cohorts. Even if little is known about the long-term 
outcome, it seems as if most patients with a fetal first-degree AVB, normalize the PR 
interval before or at birth110. In the PRIDE study (PR Interval and Dexamethasone 
Evaluation prospective study), 2 of 95 fetuses exposed to maternal autoantibodies 
developed a PR interval exceeding 150 ms and were subsequently treated with 
dexamethasone. The PR interval normalized within a week after treatment started at 
4mg/day. A similar attempt in a study with a different definition of AV-interval 
prolongation, showed that 6 of 70 fetuses developing first-degree AVB according to the 
study’s definition, normalized the AV intervals after dexamethasone treatment and 
remained in normal SR145. In the light of spontaneous normalization in other cases of 
fetal AV interval prolongation before or at birth, the interpretation of the authors of a 
successful intervention has been questioned. 
 
2.10.2.4 Treatment to prevent development of CHB 
Attempting to prevent a subsequent development of CHB in fetuses of women with at 
least one previous pregnancy resulting in CHB, IVIG was given in early pregnancy in 
two studies. In the first study of 20 mothers, 3 children developed CAVB147 whereas in 
the second study 3/15 developed CAVB149, which corresponds well to the expected 
outcome in an untreated cohort of risk pregnancies, indicating no preventive effect 
from the treatment. 
 
2.10.2.5 Improved long-term survival or decreased morbidity with treatment? 
The small retrospective studies claiming an effect on survival after transplacental 
steroid treatment of CHB are not convincing. Considering the risk of both maternal and 
fetal side effects, further studies are needed. Regarding a possible effect on morbidity 
and development of dilated cardiomyopathy, we have no results thus far that support a 
preventive effect of steroid treatment 
 
2.10.2.6 Side effects with steroid treatment 
Side effects connected with transplacental steroid treatment are well known; in both 
mother and the fetus. In the mother all types of side effects connected with steroid 
treatment can occur, including hypertension, diabetes, adrenal insufficiency and even 
psychotic disorders. In the fetus the most commonly reported side effects include 
growth restrictions, oligohydramniosis, premature delivery and contraction of the 
ductus arteriosus116, 127, 133, 150. It can however, in each specific case, be difficult to 
separate possible side effects from the consequences of the disease itself, which can be 
connected with growth restrictions and a poor general outcome including fetal demise. 
Worries have furthermore been expressed concerning a possible negative impact on the 
neuropsychological development in children who in fetal life were exposed to treatment 
with fluorinated steroids. Most studies have been performed in patients with other 
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treatment indications than CHB. In one study, a reduction in birth head circumference 
was seen151, whereas, in another study, an increased risk of leukomalacia and 
neurodevelopmental abnormalities was seen in children previously treated with 
dexamethasone but not in those treated with betamethasone152. In a small study on 11 
children with CHB and previously exposed to transplacental steroid treatment, all had a 
normal neuropsychological development at follow-up.153. The study comparing 
dexamethasone and betamethasone has however made many fetal cardiologist more 
prone to using betamethasone.   
 
2.10.2.7 Summary- treatment 
Taking all these results together, there is no evidence in current knowledge supporting 
transplacental treatment of a developed CAVB. Randomized studies are however 
lacking and retrospective are small and not conclusive. Fetal first degree AVB 
generally seems to revert to normal SR at birth in most cases, with or without 
treatment. Long term follow-up studies are however lacking. Single cases of rapid 
progression from first degree AVB to CAVB within a week or less, suggest that there is 
a subgroup of patients with a more severe response to antibody exposure. 
The multiple case reports on a transitory or possibly long term response with reversion 
to SR or first-degree AVB after steroid treatment in cases of second-degree AVB, 
suggest that there is a time-window in which reversal is possible, supported by the fact 
that no cases of spontaneous reversal of antibody associated second-degree AVB have 
been reported. 
 
As a natural consequence of the limited knowledge of the effect of fetal steroid 
treatment in CHB, the multinational, multicenter study on steroid treatment of isolated 
CHB was undertaken in 2008, after an initiative by the Fetal Working Group of AEPC 
(Paper II).  
 
 
2.10.3 Pacemaker treatment 
The first report of a pacemaker implanted in a child with a heart block was presented in 
1962. It was a 7- year- old child with a postoperative complete AVB154. Only small 
series of patients were reported in the following years, until a study in 1976 reported on 
24 children with a PM implanted at age 9,7 years on average155. Initially, the therapy 
was associated with a high risk of complications and the pacemakers were not designed 
for children, often pacing at a fixed rate. They were heavy and did not have the 
flexibility that modern pacemakers have. Complications were common. As a 
consequence, the strategy for a long time was to wait “as long as possible” which 
sometimes meant that some patients had developed dilated cardiomyopathy (DCMP) 
before they underwent PM implantation. Others may have experienced sudden death in 
spite of a seemingly good cardiac status. Following the study by Michaëlsson et al90, 
where it was shown that even asymptomatic patients over 15 years of age were at risk 
for sudden death, new treatment strategies were adopted almost universally and 
reflected in international guidelines of PM treatment in the young.  
 
Class I indications for pacing in isolated CAVB include a low ventricular heart rate    
(< 55 in the newborn and <50 beyond first year of life), ventricular dysfunction, 
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instable or wide complex escape rhythm or abrupt pauses. While the community of 
pediatric cardiology more or less agree regarding the indications for pacing, the 
positions diverge on type (epicardial or endocardial) and mode (VVI or DDD) at what 
age. This is reflected in the latest consensus document from the European Association 
of Pediatric Cardiology (AEPC) and the European Heart Rhythm Association 
(EHRA)92. As an example, where for instance left ventricular epicardial VVI pacing 
would be the recommended approach in a CAVB patient weighing <10kg, an 
endocardial PM could also be recommendable due to “center preference”. This 
approach is probably supported by the concept that the outcome in a single case will 
depend on the skills and the experience of the surgeon or the implanting cardiologist, 
with respect to the chosen method. 
 
Risks of complications connected with pacing are known to be substantial in children, 
even if only limited data on complications in the recent era are available. Complications 
following pacing depend on multiple factors. At least one previous study has shown 
that a young age at first PM implantation is associated with a higher number of 
complications156. Lead related problems are the most common, reported to be more 
frequent in epicardial pacing157, whereas obstructed veins and lead dislodgements are 
more frequent in endocardial pacing, as well as rare complications like cardiac 
perforation and tamponade. A relatively frequent and threatening complication is an 
infection of the pacing system, occurring in (1-8%) of pediatric patients, often 
necessitating explantation of the entire pacing system158, 159. One problem with most 
previous studies however, is that complications are compared in mixed patient groups, 
including postoperative heart block and patients with complex structural heart disease. 
Patients in such mixed groups may, on a group level, have a different risk of 
experiencing pacing-related complications than patients with isolated CHB. There are 
to date no studies evaluating risk factors for pacing-related complications exclusively in 
patients with isolated CHB.  
 
Ever since the first reports on late development of DCMP after years of pacing160, 161, 
growing attention has been directed towards the possibility of pacing- induced 
cardiomyopathy, namely by right ventricular (RV) pacing, especially from the apex. 
The clinical reports have been accompanied by experimental studies showing the 
hemodynamically negative consequences compared with left ventricular (LV) pacing, 
assumed to be due mainly to pacing induced dyssynchrony162-165. The results are 
theoretically convincing but is the type of pacing really to blame for all patients 
developing DCMP? If not, then to what extent? 
 
There are several points to consider when evaluating this: RV pacing has been the 
dominant type of pacing for many years and most studies reporting on outcome of 
CAVB patients and pacemaker therapy have an overwhelming dominance of RV paced 
patients. For obvious reasons this makes a fair comparison between LV and RV pacing 
difficult, if not impossible. Many pediatric cardiologists would agree that RV apical 
pacing is not the optimal pacing site and should be avoided if possible. Left ventricular 
pacing may offer hemodynamic advantages compared with other pacing sites but to 
what extent can/should this be translated to a clinical context? Many cardiologists 
would probably opt for a LV epicardial pacing system in a patient <15 kg, but is there 
really evidence for LV pacing being superior to RV septal pacing for older patients? It 
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is a fact that most patients with RV pacing do not develop DCMP in spite of pacing for 
10 years and more. Another problem with most studies is that the cardiac status prior to 
pacing is not taken into account when group comparisons are performed 
 
How is life with a pacemaker? 
Carrying a pacemaker surely has an impact on young person’s life, even in the absence 
of particular problems connected with pacing or symptoms related to the heart 
condition. Although the general impression from clinical practice is that most children 
seem to cope rather well with the situation of being a pacemaker carrier, there are few 
studies in this group of patients. More is actually known about children and adults 
regarding psychosocial aspects in ICD carriers than in young patients with pacemakers. 
There are however a few recent publications investigating these aspects. In a study by 
Webster et al166 a group of adolescents with PM were compared with a group of 
patients with implantable cardioverter defibrillators (ICD). Standardized structured 
psychiatric interviews and self-report questionnaires were used. Patients with ICD and 
PM had similar psycho-social functioning but lower physical Quality of Life (QoL) 
scores compared with a normal reference population. Patients with an ICD had higher 
rates of anxiety disorders than did patients with a PM. In another study of patients with 
CAVB and Right ventricular pacing questionnaires assessing health-related quality of 
life (HRQoL) were used167. Possible associations with functional capacity were tested 
using the 6 minute walk -distance test (6MWDT). Almost all patients had received their 
PM in childhood but were adolescents or young adults (mean age 21.5 years) at the 
time of evaluation. The study showed that chronic RV pacing in this group did not 
seem to affect overall HRQoL. Female gender, decreased left ventricular function and 
cardiac drug therapy were associated with lower scores. A third study, also using 
HRQoL, included 27 children and adolescents with a mean age of 14 years, where the 
majority had isolated heart block168. The results showed that the studied group had 
lower overall levels of HRQoL compared with healthy norms, as indicated by both the 
so called proxy-report as the child self-report. So what do these studies tell us? In my 
view it is difficult to draw any general conclusions due to the different methods and 
varying study groups, as well as study design. Another question arising is if the study 
design- and approach really captures the whole picture? A qualitative research 
approach would perhaps be more useful as it could pinpoint the specific situation and 
possible problems connected with carrying a pacemaker. 
 
 
Cardiac resynchronization therapy 
The basic goal and principle of Cardiac resynchronization therapy (CRT) is to restore 
synchrony of the left ventricle in patients who have developed dilated cardiomyopathy 
in combination with dyssynchrony of the LV. Limiting the discussion to patients with 
isolated CHB and pacemaker treatment, the problem of dyssynchrony after RV pacing 
in some patients has been described above. Data supporting this therapy in children are 
much more limited than in adults. In the pediatric group, the best responders seem to be 
patients upgraded from RV pacing to CRT169, 170. There is, however, a spectrum from 
non-responders to a completely normalized LVF in single cases. Long-term follow-up 
of patients with exclusively isolated CHB and CRT are to date missing. 
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2.11 PROGNOSIS 
As mentioned earlier, the course of this disease has changed in a positive way over the 
last decades, mostly thanks to the introduction of pacemaker therapy at an early age. As 
a whole, mortality is still high if we include fetal demise, usually 15-30%. For a child 
who survives the neonatal period without early development of dilated 
cardiomyopathy, the outlook is much better. Several studies have indicated that a small 
proportion of patients may, however, develop late onset left ventricular (LV) 
dysfunction, in spite of pacing therapy compliant with guidelines and international 
recommendations. The risk factors associated with development of LV dysfunction are 
not clear, although exposure to maternal autoantibodies is suggested to be one of them. 
Another suggested risk factor is RV pacing.  
 
Children who in fetal life were exposed to maternal autoantibodies without developing 
complete AVB are considered out of risk for subsequent disease development. Long-
term follow-up of both this group and individuals who developed transitory conduction 
abnormalities in fetal life, are lacking.  
 
Complications to pacemaker treatment are unfortunately relatively common even in the 
short- term, mainly pacing lead- related complications, but also infections, and smaller 
risks for serious complications, such as perforation of the myocardium in connection 
with implantation of endocardial pacemakers. We still have relatively limited 
knowledge about the long-term outcome for patients with isolated CHB; most studies 
so far do not separate this group from other groups with complex structural heart 
disease. While pacemakers were implanted in children already during the 1960s, the 
receivers were almost exclusively very diseased and most of them died. It is only in the 
last few decades that children without symptoms more systematically undergo PM 
treatment. This means that we have relatively little long term data as grounds for what 
the consequences will be like in terms of complications and clinical symptoms as a 
whole.  
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3 AIMS 
 
The general aims of this thesis were to increase knowledge of the clinical consequences 
of fetal exposure to maternal SSA-Ro and/or SSB-La autoantibodies, focusing on those 
individuals who develop complete heart block 
 
The specific aims were: 
 
 To study the underlying substrates in fetal bradyarrhythmia and the accuracy of 
Echo Doppler techniques in differential diagnostics, specifically in 
distinguishing benign conditions from potentially lethal ones 
 
 To compare the outcome in fetuses with second- and third degree AVB given 
vs not given transplacental treatment with fluorinated steroids, in respect to 
morbidity and mortality and to identify risk factors associated with a poor 
outcome  
 
 To study cardiac- function and conduction properties in pre-school children 
who had been exposed to maternal SSA-Ro autoantibodies in utero, without 
developing complete heart block 
 
 To study the outcome after pacemaker therapy in children exposed to maternal 
autoantibodies compared with unexposed, with specific focus on heart function 
at follow-up and to identify risk factors of a poor outcome 
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4 METHODS 
 
4.1 STUDY SUBJECTS AND METHODS 
4.1.1 Paper I 
4.1.1.1 Patients and study design 
In a single center, retrospective study, all patients referred to Astrid Lindgren 
Children’s Hospital for evaluation of fetal bradycardia between 1990 and 2007 were 
identified through a search of the local database. Data from 75 pregnant women were 
retrieved. Three additional cases of fetal bradycardia, detected during 
echocardiographic surveillance of anti-Ro52 antibody positive pregnancies, were also 
included for further evaluation. The reports from fetal and neonatal cardiac 
examinations performed on these 78 cases were analyzed and video and/or digital 
records re-evaluated.  
 
4.1.1.2 Definitions and inclusion criteria 
Bradycardia was defined as a heart rate ≤ 110 bpm; classified as sustained only if the 
fetus remained in bradycardia for the entire 45 minutes of examination. Cases with an 
irregular heart rhythm were not included. 
 
4.1.1.3 Echocardiographic recordings 
M-mode echocardiograms and Doppler recordings from the mitral valve/aorta were 
used from the beginning of the study period. Doppler recordings from the superior vena 
cava/aorta, as well as from a pulmonary vein and a peripheral pulmonary artery came 
into use around 2000, whereas recordings from the pulmonary trunk and the ductus 
venosus have been used from 2003 and onwards. Recordings from the pulmonary trunk 
were obtained from any view with a narrow angle of insonation and the sampling 
volume adjusted to the flow in or just above the pulmonary valve. Besides typical 
systolic outflow profiles these recordings also comprised very sharp late diastolic 
antegrade flow profiles, corresponding to atrial contractions. Doppler recordings of the 
ductus venosus were obtained in a midsagittal or transverse section.  
 
4.1.1.4 Classification of arrhythmias 
Identification of the electrophysiological mechanism generating the bradycardia was 
based on recognition of the chronological relationships between atrial (A) and 
ventricular (V) depolarization, which were in turn identified by their mechanical (M-
mode) or hemodynamic (Doppler) consequences. Fetuses with a regular ventricular 
rhythm and 1:1 AV relationship were considered to be in sinus rhythm. In case of a 
regular ventricular rhythm and 2:1 AV relationship, the AA time interval was further 
analyzed. If every second atrial contraction was premature, resulting in a pattern where 
a shorter AA interval was systematically alternating with a longer interval, the fetus 
was diagnosed to have BB. If AA time intervals were constant, a second recording was 
made to compare the AV intervals with those from the first recordings. When the AV 
intervals remained unchanged between these two examinations, the diagnosis of 
second-degree AVB was made. In case of AV dissociation at the first or second 
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recording the fetus was diagnosed as having third-degree AVB. To more meticulously 
investigate the AA intervals in fetuses with BB and second-degree AVB, a ratio was 
constructed by dividing the time interval between the conducted and consecutive 
blocked atrial contraction (acb) with the time interval between two conducted atrial 
beats (acb/acc ratio). Heart rate was assessed from any of the Doppler tracings with 
arterial flow profiles. All measurements were made on three consecutive velocity 
waveforms, using the electronic calipers on the ultrasound machine, and averaged. 
 
4.1.2 Paper II 
4.1.2.1 Patients and study design  
In a retrospective, multicenter, multinational study, all members of the Fetal Working 
Group (FWG) of the European Association of Pediatric Cardiology were invited to 
contribute data of fetuses diagnosed with isolated second-degree AVB (AVB II) or 
third-degree AVB (AVB III) from 2000 to 2007. Data on 189 patients from 28 
contributing centers in 15 countries were submitted. 
 
4.1.2.2 Criteria for exclusion and inclusion  
Fourteen fetuses were excluded after data evaluation. In 10 cases no birth outcome data 
was available and in 4 cases, claimed to have reverted from AVB II or III, 
documentation was lacking (n=2) or the initial diagnosis of AVB could not be 
retrospectively confirmed (n=2). The resulting final study population consisted of 175 
fetuses diagnosed with isolated AVB II or III and a minimum follow-up time from 
diagnosis until birth or intrauterine death. Cases of AVB demonstrating improved 
atrioventricular conduction were only included if accompanied by M-mode or Doppler 
recordings confirming the diagnosis.  
 
4.1.2.3 Data collection and methods 
All cases had been diagnosed by a fetal cardiologist at each center using standard fetal 
echocardiographic techniques. The examination diagnosed the arrhythmia, evaluated 
cardiac function and hemodynamics and excluded major cardiac malformations known 
to be associated with heart block. Data were collected retrospectively through review of 
the clinical charts and echocardiographic examinations at each of the participating 
centers and sent to the study coordinator. The collected data included: (1) maternal 
data; age, presence of autoimmune disease and autoantibodies (SSA-Ro/SSB-La), 
steroid treatment at time of conception, parity and previous fetuses with AVB, (2) fetal 
data; gestational age, degree of AVB, atrial and ventricular rate, left ventricular 
function and presence of hydrops,  (3) pharmacological treatment; steroids (type, dose, 
duration), betamimetics (type, dose, duration) and documented fetal and/or maternal 
complications; (4) fetal outcome: survival and cardiac status; (5) the child at birth/ 
follow-up: date of birth, gestational age, birth weight, degree of AVB, ventricular rate, 
age at last follow-up or death.  Pacing and development of cardiomyopathy were 
documented. Transplacental steroid treatment was only considered present when the 
pregnant mothers were given fluorinated steroids. Hydrops was defined as serous 
effusions in at least two compartments.  
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4.1.2.4 Methods and group comparisons 
Cases were divided into groups based on placental treatment (steroid treated or 
untreated) and outcome at birth and 1 month of age (survival or death), respectively. 
All patients alive at birth, except 11 patients lost to follow-up, were assessed for 
neonatal mortality. These analyses were also performed on the subgroups of patients 
defined by (1) a positive anti-Ro/SSA- and/or anti-Ro/SSB test and (2) a positive test 
further restricted to AVB II-III/III. 
 
4.1.3 Paper III 
4.1.3.1 Patients and study design  
This was a single center, cross-sectional follow-up study of children exposed in utero to 
maternal anti-SSA/Ro52 autoantibodies. During 1999-2007, 83 fetuses (82 
pregnancies) in 63 anti-SSA/Ro52 autoantibody positive women followed a protocol 
for fetal echocardiography surveillance and an outcome ECG during the first week after 
birth. With the exception of five families not living within our region, one case with an 
umbilical cord complication resulting in intrauterine death and two cases of CAVB, all 
families going through our surveillance protocol were invited to let their child 
participate in a follow-up study. Parents declined participation in 18 cases, resulting in 
a final study population of 57 children. 
 
4.1.3.2 Methods 
The children of the cohort were divided into two groups: AV time interval prolongation 
(group A) and normal findings (group B) in utero, and compared on a group basis as 
well as individually to published reference data. The study protocol included basic 
demographic data as well as clinical history, physical examination, ECG at rest, 24-
hour Holter ECG and echocardiographic studies. 
 
4.1.3.2.1 Prenatal echocardiographic studies 
The protocol of weekly fetal echocardiographies, from 18 to 24 weeks of gestation, 
used for surveillance of fetuses at risk for CAVB has been described elsewhere110, 171. 
Briefly, Doppler flow recordings from left ventricular in- and outflow (MV-Ao) and 
superior vena cava and ascending aorta (SVC-Ao) were used to measure mechanical 
AV time intervals as an indirect estimate of electrical AV conduction. Both methods 
have been validated and reference values have been established98, 106, 107, 112. For 
comparison with the PR interval on ECG, all fetal AV time measurements were 
categorized in respect to 95% and 99%  reference ranges, and considered abnormal if 
exceeding their respective upper cut off limits at two consecutive examinations. 
Individual AV time intervals were calculated by averaging the two highest 
measurements. For all other analyses, the MV-Ao time interval with a 95% reference 
range was used to assign cases to the group with prolonged AV time intervals in utero  
(group A) or the group with normal recordings (group B). 
 
4.1.3.2.2 ECG- recordings and 24 hour Holter ECG 
From a standard 12 lead ECG, measurements of heart rate (HR), QRS-duration, PR- 
and QTc intervals (using Bazett’s formula), were obtained and compared with age 
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related reference values, defining the 98th percentile as the upper normal limit172. All 
24-hour ECG recordings were analyzed by a single investigator blinded to the grouping 
of patients at time of analysis. HR was analyzed by defining its 24-hour mean, standard 
deviation, range and maximum RR interval. To standardize measurements of AV 
conduction, the PR interval was averaged over three consecutive beats, during a period 
where the HR matched the average over the whole 24-hour period. 
 
4.1.3.2.3 Pediatric echocardiographic studies 
A complete echocardiographic study was performed to rule out structural 
abnormalities. Systolic left ventricular function was studied with M-mode173 and 
diastolic function was investigated using mitral Doppler flow velocity recordings, 
where early (peak E) and active (peak A) filling velocities were measured and E/A ratio 
calculated174 The myocardial performance index (MPI), assessing combined systolic 
and diastolic function of the left ventricle, was obtained by measuring the isovolumetric 
contraction time (IVCT), isovolumetric relaxation time (IVRT) and ejection time (ET) 
intervals on recordings of mitral valve inflow and left ventricular outflow profiles, and 
calculated using the formula; MPI = (IVCT+IVRT)/ET175 . Tissue Doppler imaging 
(TDI) for evaluation of longitudinal function of the left ventricle was performed using 
two sample sites: the lateral mitral valve annulus and the basal ventricular septum. At 
each site 6 variables (peak E’, A’ and S’ velocities, IVCT’, IVRT’, ET’) were measured 
as previously described176. TDI derived myocardial performance indices (MPI’) were 
calculated as described above. IVCT’ and IVRT’ were corrected for HR (IVCT’c, 
IVRT’c) by division with the square root of the RR interval. All Doppler registrations 
were performed using a 4-chamber view and an angle of insonation within 30°. In all 
measurements, the average of 3 recorded complexes was used. 
 
4.1.4 Paper IV 
4.1.4.1 Study design and patients 
This was a nationwide, retrospective cohort study where all patients in Sweden with 
pacemaker (PM) treatment and isolated complete AVB (CAVB) diagnosed before the 
age of 15 years, were identified by searching the following registers: (1) Swedish ICD- 
and Pacemaker Registry, (2) Swedish National Patient Registry and (3) local clinical 
patient registries, as well as through a network of pediatricians, cardiologists and 
rheumatologists at six university hospitals in Sweden. All patients were cross-matched 
to the Swedish Malformation Registry as well as the Swedish Heart Surgery Registry in 
order to exclude patients with CAVB due to a cardiac malformation or as a result of 
heart surgery. To evaluate mortality among patients with isolated CAVB and PM, the 
Swedish Cause of Death Registry was searched. Heart transplantation was in the 
context of this study equated with death.  
 
 
A total of 168 pacemaker treated patients with a diagnosis of AVB <15 years of age, 
born 1980 to 2011 were identified. Eleven patients were excluded as they did not 
respond to at least two letters (n=5), or declined participation (n=6).  
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Patient records were collected and examined for assessment of eligibility. Thirty of the 
patients did not meet the inclusion criteria and were excluded. Patients with advanced 
second to third degree AVB and permanent pacing, were classified as CAVB and 
included in the study. Permanent pacing was defined as ventricular pacing >99% of the 
time. 
 
4.1.4.2 Methods 
The final study population consisted of 127 patients and observational data were 
collected retrospectively by review of the clinical charts. Briefly, the collected data 
included information on presence of maternal autoimmune disease and exposure to 
autoantibodies (SSA-Ro/SSB-La), gestational age (GA), degree of AVB, transplacental 
treatment with steroids or betamimetics and status at fetal presentation. Neonatal- and 
childhood data included: cardiac status, signs of extracardiac disease or symptoms, 
treatment with beta-adrenergic agonists. 
 
Electrocardiography (ECG): Tracings were reviewed and analyzed for rhythm and 
heart rate at diagnosis. Echocardiographic examinations: Data were collected and 
registered regarding heart function and presence of structural heart disease. Patients 
with associated structural abnormalities were only included if the defect was not 
considered causal of the heart block. Data on left ventricular function (LVF) at birth 
and at FU were collected: (1) left ventricular end diastolic dimensions (LVEDD), (2) 
left ventricular fractional shortening (FS) values. In cases where these data were not 
documented, the qualitative description of the LVF by the examiner was used and 
classified as normal, borderline or impaired. To enable comparisons across age groups, 
LVEDD values were transformed to a body surface related z-score (LVEDD z-score)177 
and FS values were transformed to an age related z- score (FS z-score)178. Ejection 
fraction (EF) values were reported when present. To enable categorical comparisons, 
LVF was additionally classified as normal (LVEDD z-score <2 and FS z-score > -2), 
borderline (LVEDD z-score > 2 or FS z-score <-2) or impaired (LVEDD z-score > 2 
and FS z-score < -2), or according to the classification by the examiner whenever either 
of the values were missing. Most patients had been examined using echocardiography 
(echo) at several occasions but the data presented in the study are: echo before PM 
treatment and echo at last FU and, if appropriate, echo at diagnosis of impaired LVF.  
 
Pacing data were collected through the Swedish ICD- and Pacemaker Registry or the 
patient records, including age and date of PM implantations, type and mode of pacing, 
characteristics of pacemakers and electrodes as well as data on complications. A 
complication was defined as any occurring event leading to an unforeseen re-
intervention of the pacing system. The events were further classified as early (< 3 
months) or late (> 3 months) with respect to time from previous intervention. To 
evaluate possible changes over time in mode or type of pacing, the cohort was divided 
arbitrarily into an early period (1983-2000) and a late period (2001-2011).  
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4.2 STATISTICAL ANALYSES 
Overall 
In all papers, comparisons of normally distributed continuous variables were performed 
using two sample t-test and measures presented as mean and standard deviation. 
Continuous variables with a skewed distribution were compared using Wilcoxon’s two 
sample test or Mann-Whitney U-test when appropriate; variables presented as median 
and range. Comparisons of frequencies with respect to categorical variables were 
performed using Fisher’s exact tests or Pearson Chi square test as appropriate. The 
level of statistical significance was set at p<0,05 in all papers. 
 
4.2.1 Paper I 
Comparisons with respect to gestational age or fetal heart rate between patients with 
different arrhythmia substrates were performed using one-way ANOVA with Tukey 
HSD test. 
 
4.2.2 Paper II 
Cases were divided into groups based on placental steroid treatment (treated vs 
untreated) and outcome at birth and 1 month of age (survival or death), respectively.  
Intrauterine mortality and neonatal mortality with respect to steroid treatment were 
analyzed separately, where all patients were assessed for intrauterine mortality. All 
patients alive at birth, except 11 patients lost to follow-up, were assessed for neonatal 
mortality. Both these outcomes were analyzed by exact logistic regression including 
only steroid treatment and an adjusted model conditioned on gestational age at 
diagnosis (categorized as <20, 20-24,25-29, ≥30 weeks). These analyses were also 
performed on the subgroups of patients defined by a positive anti-Ro/SSA- and/or anti-
Ro/SSB test (1), and a positive test further restricted to AVB II-III/III (2). Results of the 
logistic regressions are presented as odds ratios with exact 95% confidence limits.  
 
The analysis of the effect of betamimetics on heart rate included only patients with data 
on ventricular rate both prior to initiation of treatment and within two weeks after 
initiation. Follow-up of the cohort beyond the neonatal period is incomplete with 
missing information about the time-points when patients were lost to follow-up. Data 
on long-term outcomes and characteristics are therefore purely descriptive 
 
4.2.3 Paper III 
Linear regression was used to analyze relationships between flow velocity and tissue 
Doppler variables on one hand, and the PR interval on the other hand. For analysis of 
sensitivity, specificity, positive and negative predictive value (PPV and NPV), positive 
and negative likelihood ratio (LR+ and LR-) with their 95% confidence intervals, the 
Vassar Stats Clinical Research Calculator 1 was used179.  
 
4.2.4 Paper IV 
Kolmogorov-Smirnov test was used to test continuous variables for normality. Uni- and 
multivariate Cox regression analyses were performed in the comparison of possible 
event (complication) predictors. Hazard ratio with 95% confidence intervals were 
calculated for each covariate. A p-value <0,05 was considered significant. 
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4.3 ETHICAL CONSIDERATIONS 
 
Studies I, III and IV were evaluated and approved by the Ethics Committee at 
Karolinska University Hospital. The multinational, multicenter study (study II), was 
evaluated by the National Research Ethics Committee (Hammersmith and Queen 
Charlotte’s and Chelsea research Ethics Committee, 2007) and considered to not 
require review by a National Health Service Research Ethics Committee. In practice, 
this study was also locally approved by the Ethics Committee at Karolinska University 
Hospital, as Stockholm data for study II was extracted from study I. 
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5 RESULTS 
 
General remark: The central and most important results of each paper are presented in 
this section. For complete results, please see published papers (I-III) and the final paper 
in manuscript form (paper IV). 
 
5.1 PAPER I 
The aims of this study were to assess the underlying mechanisms in fetal 
bradyarrhythmia and the diagnostic accuracy of Echo Doppler techniques.  
 
Sixty-five patients had a HR< 110/min; table 5.1 details the underlying arrhythmic 
substrates. Forty-two patients had sustained bradycardia; in 20 cases the underlying 
rhythm was a complete AVB, in 5 cases a second-degree AVB, in 6 blocked 
bigeminies (BB) and sinus bradycardia (SB) was seen in a further 11 patients. All 23 
patients with intermittent bradycardia had BB and 4 of them developed supraventricular 
tachycardia. Patients with constantly blocked BB were diagnosed earlier than those 
with intermittent tachycardia and 7 of 11 patients with SB had a potentially serious 
underlying condition. 
 
 
Table 5.1. Diagnosis and clinical characteristics in 65 pregnancies with fetal bradycardia 
(Heart rate ≤ 110 bpm). 
 
Arrhythmia 
 
No GA CHD LQTS SVT TOP HR 
(3°) AVB 20 23.2±4.4 7   3/4 56.9±10.3 
(2°) AVB 5 20.8±2.5 1 1  1/0 67.4±6.0 
Sustained 
BB 
6 19.3±4.8    1/0 75.7±5.3b 
Intermittent 
BB 
23 31.1±5.7b, d, h 1  4 0/0 77.3±7.2b 
Sinus 
bradycardia 
11 29.4±6.3a, c, g 3 3  0/1 105±2.7b, e, h, i 
 
Values are mean ± 1 SD. ap < 0.05, bp < 0.001 (vs. 3°AVB), cp < 0.05, dp < 0.01, ep < 0.001 (vs. 2°AVB), 
fp < 0.05, gp < 0.01, hp < 0.001 (vs. Sustained BB), ip < 0.001 (vs. Intermittent BB). n, number of fetuses; 
AVB, atrioventrickular block; BB, blocked atrial bigeminy; CHD, congenital heart disease; LQTS, long 
QT syndrome; SVT, supraventricular tachycardia 
 
Diagnostic Accuracy 
 
A correct prenatal diagnosis was made in all cases but one; a case with sustained fetal 
bradycardia where a postnatal ECG verified an ectopic rhythm. In one further case, the 
correct diagnosis was considered at the second examination but confirmed only 
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postnatally. This was a case of functional second-degree AVB due to long QT 
syndrome where 1:1 conduction was intermittently restored at the second examination. 
 
Visual validation of the Doppler recordings was usually sufficient to determine the 
arrhythmic substrate. In 7 cases a recording from the pulmonary trunk clearly 
differentiated between second- and third degree AVB. Good quality recordings from 
the ductus venosus were available in 12 cases, making a differentiation between BB 
and second degree AVB feasible. Meticulous measurements of time intervals were 
needed only in a few midgestational cases of sustained BB, with a constant 2:1 relation 
between atrial and ventricular beats. Five of 6 cases with sustained BB, diagnosed in 
early gestation, had surprisingly long acb intervals and acb/acc ratios, similar to the cases 
of second degree AVB, illustrated in figure 5.1. Heart rates < 65 bpm were not seen in  
BB and a HR<60 bpm was seen only in complete AVB. The cases with SB all had a 
stable HR between 100 and 110.   
 
 
 
Figure 5.1. Fetal heart rate (left panel) and the Doppler time interval between the conducted and 
following blocked atrial contraction divided by the time interval between two conducted atrial beats 
(acb/acc ratio, right panel) plotted against the gestational age at the first echocardiographic examination. 
3°AVB, complete atrioventricular block; 2°AVB, second-degree AVB; BBs, sustained blocked atrial 
bigeminy; BBi, intermittent blocked atrial bigeminy; SR, sinus rhythm. 
 
 
5.2 PAPER II 
The overall aims of this study were to investigate prognostic factors associated with a 
poor outcome and the effect of transplacental steroid treatment in fetal second- and 
third- degree AVB. 
 
Eighty percent of the patients were exposed to maternal autoantibodies (Anti-Ro/SSA-
positive) and maternal collagen disease was present in 46%. Eighty-three percent had 
AVB III, 9% AVB II and 8% AVB II-III at the time of diagnosis.   
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Transplacental treatment 
Sixty-seven fetuses (38%) were treated with fluorinated steroids; 52 were given 
dexamethasone at a median starting dose of 4 mg/day (2-12 mg) and 15 received 
betamethasone at 4 mg/day (3-5 mg). In two cases, fluorinated steroids were given in 
combination with prednisolone. The duration of treatment was median 10 (1-21) weeks 
and remained unchanged in most cases. Side effects in the child were reported in 11 
pregnancies (oligohydramniosis, growth restriction and constriction of the arterial duct) 
whereas only one mother was reported to have side effects from the treatment (diabetes 
mellitus, adrenal insufficiency and psychosis). Betamimetics were given to 41 fetuses 
(23%) at median gestation 25 weeks (19-33) for a median duration of 8 weeks (2-18). 
Ventricular heart rate (VHR) increased from 50.1±3.8 to 55.1±3.7 bpm (p=0.001) in the 
15 patients where data were available prior to as well as after two weeks of treatment. 
Betamimetics were more frequently given in combination with steroid treatment than as 
a single therapy (23/67 vs 18/108; p=0,01). 
 
Overall outcome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.1 The overall outcome of the patients included in the study. 
 
 
 
Survival at birth and in the neonatal period 
Ninety-one percent (159/175) were alive at birth and a further 10 of these patients died 
during the first month (=neonatal death). There were no differences in survival at birth 
or at 1 month of age with respect to steroid-treated and untreated fetuses (Table 5.2.1). 
Restricting the comparison to antibody exposed fetuses did not influence the results 
significantly. Steroid treatment in the group with at least one risk factor associated with 
a poor outcome at the time of diagnosis, did not have any significant effect on outcome. 
Adjusting for the small difference between the groups in gestational age at diagnosis 
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did not have any significant effect on the results. There were no differences between 
steroid-treated and untreated in the following variables at the time of diagnosis; Anti-
Ro/SSA exposure: 86 vs 76% (p=0.25),Ventricular HR: 61.3 ± 11.3 vs 58.9 ± 11.5 
(p=0.19), Impaired left ventricular function: 13 vs 12% (p=0.84), Hydrops: 7 vs 10% 
(p=0.54).  
 
 
Table 5.2.1 Transplacental steroid treatment and outcome of all 175 included fetuses (at birth) 
and the 148 live born neonates with known outcome at one month of age. 
 
Categories All patients Steroid 
treated 
Untreated OR- crude OR-adjusted 
Survival 
At birth 
     
All 
fetuses 
91% (159/175) 91% (61/67)  91% (98/108) 0.96 (0.27-3.10) 0.79 (0.21-2.67) 
AB+ 91% (119/131) 91% (51/56) 91% (68/75) 0.95 (0.22-3.72) 0.85 (0.20-3.41) 
AB+ and 
AVB III 
 
90% (109/121) 
 
90% (44/49) 
 
90% (65/72) 
 
1.05 (0.25-4.15) 
 
0.97 (0.22-3.96) 
Survival 
1 month 
     
All 
neonates 
93% (138/148) 95% (53/56) 92% (85/92) 0.69 (0.11-3.18) 0.58 (0.23-1.79) 
AB+ 95% (103/108) 96% (44/46) 95% (59/62) 0.89 (0.07-8.16) 1.00 (0.08-10.2) 
AB+ and 
AVB III 
95% (96/101) 95% (39/41) 95% (57/60) 0.97 (0.08-8.92) 1.04 (0.08-10.7) 
AB+; Anti-Ro/SSA and/or La/SSB positive, OR-crude; unadjusted odds ratio, OR-adjusted; odds ratio 
adjusted for gestational age (categorized as <20, 20-24, 25-29, 30 weeks). OR is presented with 95% 
confidence limits; all other results as percent and number of cases.  
  
 
Risk factors associated with a poor outcome 
Gestational age (GA) at diagnosis was higher in survivors at birth and at 1 month 
compared with non survivors. Ventricular HR was higher in survivors than non-
survivors at birth; 60.8 ± 10.9 vs 49.9 ± 11.8 ( p=0.0002), whereas no significant 
difference was seen in survivors vs non-survivors at 1 month of age; 61.0 ± 10.8 vs 
59.6 ± 14.6 (p=0.70). Intrauterine mortality was around 4 times higher in fetuses 
diagnosed with AVB diagnosed at GA< 20 weeks compared with > 23 weeks and 5 
times higher in fetuses with a VHR ≤50 bpm compared with >55 bpm. The presence of 
impaired LVF and hydrops increased both intrauterine - and neonatal mortality by a 
factor of 4 and 6, respectively. 
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Figure 5.2.2. below shows the effects of the presence of at least one of these risk factors 
on survival outcome. 
 
 
 
Figure 5.2.2. Intrauterine (panel A, n=107) and neonatal (panel B, n=90) mortality in fetuses with known 
presence or absence of risk factors (RF) at diagnosis, AVB II-III/III and fetal exposure to maternal anti-
Ro/SSA and/or La/SSB antibodies. Mortality is shown by treatment group in the figure legend. High risk 
denotes the presence of at least one risk factor; GA <20 weeks, ventricular rate ≤50 bpm, presence of 
hydrops or impaired LV-function. Low risk are those without any risk factor. Numbers on top of bars are 
number (n) of cases. Comparisons are treated vs untreated patients. 
 
Steroid treatment and atrioventrcular conduction 
Nine percent (15/175) of the fetuses had AVB II, diagnosed at GA 22 weeks (19-29) of 
which 10 were exposed to maternal antibodies, 4 were unexposed and in 1 case there 
was no information on exposure. Eight percent were reported to have AVB II-III, 
diagnosed at 21 weeks (19-31); 10 were exposed to maternal antibodies, 3 unexposed 
and 1 unknown. Briefly, of the 7 fetuses with AVB II, 3 reverted to 1:1 conduction 
within 1-2 weeks after treatment and were in sinus rhythm (SR) at birth. At FU, only 
one was known to be in SR (1 year of age), whereas one had progressed to AVB I-II (5 
years of age) and in one there was no information. Six of 14 fetuses with AVB II-III 
were treated with steroids, of whom one reverted to 1:1 conduction within weeks after 
initiation of steroid treatment. The patient had however progressed to AVB III at FU (4 
years of age). Another patient (unexposed to antibodies) reverted from AVB I-III to SR 
after steroid treatment at 21 weeks of GA and remained in SR at FU (2.7 years of age).  
 
Postnatal outcome 
One hundred and thirty-eight patients were alive at FU (Figure 5.1.1) at an average age 
of 3.3 years. Two infants died between 1 month and 1 year of age and 2 died after 1 
year of age. Eight patients (6/8 exposed to antibodies) developed dilated 
cardiomyopathy. A permanent pacemaker (PM) was implanted in 102 patients of whom 
60 (43%) of the children alive at 1 month were paced. Eighty-one percent had an 
epicardial PM system implanted at a median age of 10 days (1 day-7.9 years) and 19% 
an endocardial system at median 2 months (1 day-2.2 years). 
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5.3 PAPER III 
The overall aim was to study the outcome of fetal exposure to maternal anti -SSA/Ro 
antibodies in children who did not develop complete atrioventricular block (CAVB). 
 
Of the 16 children with AV time interval prolongation in utero (group A), 9 had first-
degree AVB (AVB I) on ECG at birth and 8/9 had a normal ECG at 1 month of age; 
one was lost to follow-up. Two of the 8 patients had a fetal history of transient second-
degree AVB reverting to 1:1 conduction after transplacental tretament with 
betamethasone. Of the 41 children with normal findings in utero (group B), only one 
had a transient first-degree AVB on ECG at birth. The age at postnatal FU was median 
4 (0,8-8) years; 26 boys and 31 girls. None of the children had any cardiac symptoms. 
Two children with a fetal history of AV time interval prolongation and a skin lesion 
after birth, also had AVB I at FU. There were no differences between the groups in 
respect to gender, age, height or weight. 
 
Electrical conduction at FU 
 
ECG 
Table 5.3.1 details ECG characteristics at follow-up. Six of the 57 patients (10.5%) had 
AVB I on ECG. All 6 had prenatal AV time interval prolongation exceeding the 99% 
reference range for both the MV/Ao- and SVC/Ao Doppler methods (Figure 5.3). 
Three of 6 had AVB I at birth, normalized at FU at 1 month of age; the other 3 had 
normal ECG at birth. Of the 2 steroid treated patients with transient prenatal AVB II, 1 
had AVB I at FU and 1 had a normal ECG. 
 
 
 
 
 
Figure 5.3. Prenatal AV time intervals, measured using the MV-Ao (left panel) and SVC-Ao 
(right panel) Doppler methods against PR intervals on ECG at follow-up. Triangles denote 
individuals with prenatal atrioventricular (AV) time intervals exceeding the upper 95% 
(pointing up) or 99% (pointing down) confidence limits for normal fetuses. Diamonds represent 
the two cases with fetal second-degree AV block, reverted to first-degree AV block during 
transplacental betamethasone treatment, while circles represent cases with normal prenatal 
findings. Filled symbols are individuals with age related PR intervals defined as first-degree 
AV block at follow-up 
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24-hours Holter ECG  
Fifty-three of 57 children underwent a Holter registration and the registration was 
interpretable in 50; 12 in group A and 38 in group B. The PR interval was 
approximately 25 ms longer in group A compared with group B (Table 5.3.1). Four of 
the 6 children with AVB I where a Holter registration could be performed, had long PR 
intervals (160-220 ms). One child (aged 5.6 years) with transient AVB II in fetal life 
and AVB I at FU, had episodes of AVB II (Mobitz type 2) at night, whereas the other 
child (aged 1.9 years) with transient fetal AVB II had a normal ECG at FU but a highly 
variable PR interval (120-180 ms) on the Holter registration. QTc was normal in all 
patients.  
 
Table 5.3.1. ECG and Holter at follow-up grouped in accordance with presence of prenatal 
signs of first-degree AV block (group A) or not (group B). 
 Variables Group A Group B p-level 
ECG HR, bpm 105±28 105±19 NS 
 PR, ms 140±24 121±13 p < 0.01 
 QTc, ms 401±21 405±17 NS 
Holter HR mean, bpm 105±17 104±11 NS 
 HR min, bpm 76±17 75±11 NS 
 PR at HR mean, ms 155±35 129±15 p < 0.01 
Values are mean ± SD. HR, heart rate; PR at HR mean, PR interval at 24 hour mean heart rate 
 
 
Myocardial performance at FU 
 
M-mode of the left ventricle: All measurements were within normal limits173 without 
any differences between the groups. MV doppler: All measurements were within 
normal limits174, 175;MPI was slightly higher in group A; see Table 5.3.2 below:).  
 
Table 5.3.2. Mitral valve Doppler findings at follow-up grouped in accordance with presence of 
prenatal signs of first-degree AV block (group A) or not (group B). 
 Variables Group A Group B P-level 
MV-Doppler Peak E, m/s 0.84 ±0.14 0.86±0.12 NS 
 Peak A, m/s 0.53 ±0.09 0.55±0.08 NS 
 E/A 1.61 ±0.32 1.57±0.23 NS 
 IVCT, ms 38.4 ±7.4 35.7±5.9 NS 
 IVRT, ms 48.2 ±5.7 46.5±5.0 NS 
 MPI 0.35 ±0.03 0.33±0.02 P < 0.05 
Values are mean ± SD; E and A, early and active filling waves of the mitral valve; IVCT, 
isovolumetric contraction time; IVRT, isovolumetric relaxation time; MPI, myocardial 
performance index 
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Tissue Doppler: Table 5.3.3 details the outcome. One child, with a prenatal history of 
transient AVB II and intermittent AVB II on Holter ECG at FU, had an abnormal MPI 
(z-score 2,7), owing to prolongation of the IVCT interval. On a group level, MPI values 
were higher in group A, remaining so even after correction for heart rate, but individual 
values were within normal limits in both groups176. With the assumption that the 
mechanical cardiac performance in some way could be different in the 2 patients with 
more advanced impairment of AV- conduction in fetal life, the analyses were repeated 
after exclusion of those 2 patients. A significant difference between groups could still 
be seen for MPI (p<0,01), IVCT’ and IVCT’c from the mitral annulus and MPI’ from 
the basal septum (p<0,05), but not in MPI’ from the mitral annulus and basal septum 
IVCT’ and IVCT’c. In order to evaluate a possible influence of impaired AV-
conduction on MPI, both mitral valve and TDI measurements were related to PR 
interval on ECG; the 2 cases with a prenatal history of AVB II were excluded in this 
analysis also. There was no correlation between mitral valve MPI and the PR interval, 
whereas a weak correlation between the PR interval and MPI’ estimates was seen from 
the mitral annulus (r2=0.10; p<0.05) as well as from the basal ventricular septum 
(r2=0.19; p<0.01. 
 
 
Table 5.3.3. Tissue Doppler findings at follow-up grouped in accordance with presence of 
prenatal signs of first-degree AV block (group A) or not (group B).  
 
 Variables Group A Group B P-level 
Mitral annulus E’/A’ 2.64±0.97 2.34±0.72 NS 
 IVCT’, ms 64.0±23.6 47.5±7.7 P < 0.01 
 IVCT’c, ms 77.7±25.3 61.2±9.1 P < 0.05 
 IVRT’, ms 47.8±7.4 45.2±5.0 NS 
 IVRT’c, ms 59.0±10.4 58.3±7.8 NS 
 MPI’ 0.42±0.09 0.37±0.03 P < 0.05 
Basal septum E’/A’ 2.16±0.44 1.92±0.39 NS 
 IVCT’, ms 59.0±19.1 47.6±9.2 P < 0.05 
 IVCT’c, ms 72.5±17.6 60.6±8.8 P < 0.05 
 IVRT’, ms 47.9±6.6 43.6±4.3 NS 
 IVRT’c, ms 59.0±10.4 58.3±7.8 NS 
 MPI’ 0.40±0.05 0.36±0.03 P < 0.05 
 
Values are mean ± SD. Abbreviations as in table 5.3.2. c, correction for heart rate by division 
with the square root of the RR interval.  
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5.4 PAPER IV 
The main objectives with this study of patients with complete atrioventricular block 
diagnosed <15 years of age and pacemaker treatment, were to compare the outcome in 
patients exposed versus unexposed to maternal auto antibodies, identify risk factors 
associated with a poor outcome and describe pacing characteristics. 
 
Of 127 patients, 112 (88%) were tested for exposure to anti- SSA-Ro/SSB-La 
antibodies and 69 (62%) were exposed (AB+) while 43 (38%) unexposed (AB-). Table 
5.4.1 details the clinical characteristics. The FS z-score before PM- therapy was lower 
in AB+ than in AB- but no difference was seen in LVEDD z-score. In patients 
diagnosed in the earliest period (1981-1989) the time from diagnosis to PM 
implantation was significantly longer compared with in the later period (1999-2007); 
median 5.8 vs 0.2 years. (p=0.0003) 
 
Table 5.4.1. Comparison of clinical characteristics in children with isolated complete AVB 
(CAVB) who were exposed (AB+) or unexposed (AB-) to maternal autoantibodies. 
 All cases 
n=127 
AB+  
n=69 
AB- 
n=43 
P-value 
Gender M/F 55/72 34/35 17/26 0.34 
Age at diagnosis 
Fetal 
Neonatal 
>1 month 
 
63/127 (50) 
9 (7) 
55 (43) 
 
55/69  (80) 
6 (9) 
8 (12) 
 
5/43 (12) 
2 (5) 
36 (83) 
 
0.001 
 
0,001 
Minor cardiac 
malformations 
19/127 (15) 17/69 (25) 1/43 (2) 0,001 
Echo before PM 120/127 (94) 64/69 (93) 42/43 (98) 0,40 
FS z-score 0.91±3.2 -0.14±3.6 2.03±2,3 0.006 
LVEDD z-score 2.19±1.8 2.48±2.1 1.81±1,4 0.15 
Values are number of cases (%), the mean ± 1 SD or the median with range 
 
 
Gender and characteristics prior to pacemaker implantation 
The time from diagnosis to PM implantation was shorter in boys compared to girls; 0.2 
vs 1.0 years (p=0.03). The difference was still significant when the comparison was 
restricted to AB+ and age at diagnosis < 1 month, respectively. Median heart rate was 
lower in boys than in girls; 50 vs 60 (p=0.02), FS z-score before PM implantation was 
lower in boys; -0.19 ±3.38 vs 1.42±2.98 (p=0.02) and LVEDD z-score was higher in 
boys; 2.68 ±1.41 vs 1.74 ±1.4 (p=0.02). 
 
Pacemaker therapy 
A first PM was implanted in 127 patients at a median age of 3.2 (0.01-16.9) years. 
Fifty-five patients receiving an epicardial pacing (epi) system were significantly 
younger than 72 patients receiving an endocardial pacing (endo) system (median 0.2 vs 
7 years; p<0.0001). Ventricular single-chamber pacemakers (VVI) were implanted in 
52% (67/127); 37 vs 30 epi/endo. Twenty percent (25/126) were paced from the left 
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ventricle. At the last FU of 122 living patients at median age 15.4 years, 30% had an 
epi-system, 68% an endo-system and 2% cardiac resynchronization therapy (CRT). 
 
Pacing system revision 
In 30 patients (24 %) a re-intervention was necessary due to complications or failure of 
the pacing system. There was a total of 42 events leading to re-interventions. Twenty-
six percent (11/42) of the events occurred < 3 months after the intervention. The risk of 
an event in connection with the first implantation was almost 5 times greater for those 
who received a PM < 1 month of age than for those with pacing > 1 month of age. 
There were no significant differences in risk between epicardial vs endocardial pacing 
and DDD vs VVI pacing mode, respectively (Table 5.4.2). The year of implantation did 
not have a significant impact, although there was a possible trend towards a higher risk 
of complication the earlier a PM was implanted (in the era from 1983 to 2011); 
p=0.055. The most important reasons for a re-intervention were: pacing lead related 
complications in 22 cases (dysfunction or lead fracture in 18; dislodgement of the 
electrode in 4), infection in 11 cases, obstructed veins or fibrotic attachment of the 
leads in 3 cases and pacing leads passing foramen ovale to the left atrium or -ventricle 
in 3 cases 
 
 
Table 5.4.2. Cox proportional hazard model comparing potential risk factors for developing a 
complication in connection with the first operation. Multivariate analyses. 
 
Variable HR P-value Lower 95% CI Upper 95% CI 
Age < 1 month 
at first operation 
4.635 0.002 1.722 12.474 
Endocardial PM 0.878 0.747 0.399 1.932 
DDD PM mode 1.339 0.554 0.509 3.526 
Year of 
operation* 
0.948 0.055 0.898 1.001 
*Decreased risk per year for developing a complication compared to reference year 1983 if the 
year of implantation was delayed by one year  
 
 
Clinical outcome and echocardiographic data 
Of the 127 patients included in the study 4 died at the age of  1.2  3.8  0.7  and 17.5 
years respectively. In the first two cases the cause of death was progressive heart 
failure, in the third case a combination of respiratory insufficiency (possibly pulmonary 
hypertension) and heart failure. In the fourth case the cause of death was sudden but 
unclear. One further patient had a heart transplant at the age of 16 years, after 
progressive heart failure which commenced before PM implantation at the age of 14.5 
years. There were no significant differences in any of the comparisons regarding left 
ventricular function between AB+ and AB- at FU (Table 5.4.3). Eight patients (6%) 
reported symptoms connected with effort and 4 patients were on medication (beta-
blockers n=1, a combination of ACE-inhibitors, betablockers or spironolactone n=3).  
None of the patients with a normal LVF before PM implantation developed LV 
dysfunction. 
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Table 5.4.3. Echocardiographic data of 122 survivors* at last follow-up. Comparison of 
exposed (AB+) or unexposed (AB-) to maternal autoantibodies.  
 
 All 
n=122 
AB+ 
n=67 
AB- 
n=42 
P-value 
 
Age, y 15.5 (1,3-19) 14.7 (1.3-19) 15.6 (1.9-19)   0.92 
Pacing, y 8.8 (0.5-18,1) 10.6 (0.9-18.1) 7.2 (0.5-15.6)   0.05 
LVF     
Normal 83/117 (71) 48/67 (71) 28/42 (67)   0.67 
Borderline 30/117 (26) 16/67 (24) 13/42 (31)   0.51 
Impaired   4/117 (3)    3/67 (4)   1/42 (2)   0.50 
FS, z-score 0.16 ±2.41 -0.01 ±2.33 0,14 ±2.53   0.75 
LVEDD, z-score 1.13 ±1.49 1.24 ±1.60 1,0 ±1.40   0.45 
Values are number of cases (%), the mean ± 1SD or the median with range. *4 patients dead 
and 1 patient transplanted; last echocardiographic values not included in the comparison of 
these patients. 
 
 
Left ventricular dysfunction and predisposing factors  
Nine patients (8%) developed LV dysfunction. None of these patients had normal LVF 
before PM implantation. All patients were diagnosed at < 1 month of age, 6/7 tested 
were AB+ and the gender distribution was 2:1 male to female. Three patients (33%) 
had an epicardial left ventricular (VVI) pacing system as a first system (Table 5.4.4). At 
FU 2 patients were dead, 2 had a CRT device and 1 had a heart transplant. 
 
 
Table 5.4.4 Characteristics of patients who developed impaired left ventricular function (LVF) 
compared with cases with normal function at follow-up 
 Impaired LVF  
n=9 
Normal LVF 
n=83 
P-value 
Gender M/F 6/3 34/49 0.17 
Diagnosis < 1 month 9/9 47/83 (57) 0.01 
AB- exposure 6/7 (86) 47/75 (63) 0.41 
Normal echo before 
PM 
0/8 52/81 (64)  0.0005 
Age at PM 1.2 (0.01-14.5) 2.5 (0.01-14.9) 0.50 
LV pacing 3/9 (33) 17/83 (20) 0.41 
Values are given as number of cases (%) or the median with range.  
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Variables influencing the left ventricular function    
To evaluate the influence of AB exposure, age at diagnosis, gender, pacing duration 
and age at PM implantation on left ventricular function, LVEDD z-score and FS z-
score were compared in these groups at FU or when (if) LV dysfunction developed 
(before death or interventions like CRT, medication or heart transplant); see Table 
5.4.5. Except for a higher LVEDD z-score in patients diagnosed < 1 month of age as 
compared with those diagnosed at a later age, no significant differences were observed. 
Patients with LV dysfunction vs normal LVF prior to pacing were not equally 
distributed between groups (epi/endo, VVI/DDD, LV/RV) making a meaningful 
evaluation of the impact of type or mode of pacing on LVF  impossible.  
 
 
Table 5.4.5. Effects of clinical characteristics and PM treatment on left ventricular function 
Variables  Yes No P-value 
Diagnosis < 1 month  
 
LVEDD 
FS 
1.73±2.08 
-0.67±3.52 
0.87±1.06 
0.29±2.55 
0.02 
0.11 
Male 
 
LVEDD 
FS 
1.32±2.05 
-0.70±3.49 
1.25±1.51 
0.1±2.90 
0.85 
0.18 
AB-exposure 
 
LVEDD 
FS 
1.39±1.82 
-0.59±3.10 
1.00±1.40 
0±2.88 
0.26 
0.32 
PM< 1 month 
 
LVEDD 
FS 
1.29±1.80 
-0.90±3.43 
1.20±1.70 
0.03±3.06 
0.81 
0.16 
Pacing duration >10 
years 
(versus < 5 years) 
LVEDD 
FS 
1.48±1.76 
-0.29±3.35 
1.07±1.76 
0.16±3.60 
0.32 
0.57 
 
LVEDD and FS are expressed as z-scores (mean ± 1 SD). PM; pacemaker. 
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6 DISCUSSION 
The overarching aims of this thesis were to investigate diagnostics, pathogenesis, 
treatment and prognosis in individuals with congenital heartblock. Specifically, the 
following research questions were asked: 
 
1. Can present Echo Doppler techniques correctly diagnose and differentiate 
between benign and potentially lethal causes of fetal bradyarrhythmia?  
2. Does transplacental steroid treatment of fetuses with isolated second- or third- 
degree atrioventricular block affect outcome and what are the risk factors for 
perinatal death? 
3. Are conduction properties and heart function affected in preschool children, 
previously exposed to anti-SSA/Ro antibodies?  
4. What is the outcome after pacing therapy in children with isolated complete 
atrioventricular block and what are the risk factors associated with a poor 
outcome? 
 
  
6.1  DIAGNOSTICS OF BRADYARRHYTHMIA (PAPER I) 
 
We studied the accuracy of Doppler flow Echocardiography in diagnosing the 
underlying arrhythmia substrates in fetal bradycardia and showed that a correct 
diagnosis could be made in nearly all cases. This underlines the importance and 
usefulness of the method in the diagnostics of fetal bradyarrhythmia. 
 
The prevalence of the different underlying arrhythmic substrates compared well with a 
previous study where about half of the patients with sustained bradycardia had a 
second- or third-degree AVB and 20-30% had BB  and SB, respectively115. 
 
The majority of our cases with sustained sinus bradycardia had a significant underlying 
cardiac condition that needed intervention after birth. This has been seen in previous 
studies 115, 119, 180 and our study confirms the need for caution in managing these 
patients. 
 
With this retrospective study design, it was not possible to perform quantitative 
comparisons between the different Doppler flow recordings, but from a qualitative 
point of view we could see that they are complementary. Recordings from the 
pulmonary artery turned out to be very useful in differentiating between second- and 
third degree AVB, where sharp late-diastolic flow profiles, presumably reflecting atrial 
depolarization,  are clearly visible. It is unclear if these profiles actually reflect flow 
activity in the pulmonary trunk or in the left atrium. The ductus venosus approach was 
found to be effective in distinguishing between second-degree AVB and sustained BB 
in mid-gestation. Even if an ocular examination of the registration was sufficient to 
differentiate between these conditions in most cases, meticulous measurement by 
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applying the constructed ratio was helpful in the few cases where the intervals between 
a blocked and a conducted beat were similar. A study by Wiggins et al 181aimed at 
comparing magnetocardiography and Echo Doppler techniques in their ability to 
distinguish between BB and 2:1 AVB, concluding that diagnostics can be difficult 
using echocardiography. The Echo Doppler method they used, however, was the 
MV/Ao approach which we recognize to be inadequate in analyzing the atrial activity 
in these conditions.  In a recently published study by our group we investigated to what 
extent measurements of isovolumetric time intervals could improve differential 
diagnostics in distinguishing between BB and isolated 2:1 AVB182. Interestingly, we 
could see that the isovolumetric contraction time (ICT) interval was consistently shorter 
in BB than in 2:1 AVB.    
 
Surprisingly, mid-gestation seems to be a period where the coupling interval of 
supraventricular extrasystoles are longer than normal, compared with both late-
gestation and the postnatal period. There are however few previous published reports 
confirming this observation. With the assumption that these BB are resulting from a 
retrograde conduction over accessory pathways (AP), one could speculate that the 
conduction properties of the APs in midgestation are different from later in gestation or 
after birth. An equally intriguing phenomenon is the fact that in four of the five cases 
with BB in mid-gestation where it was possible to measure the interval between a 
conducted and a non-conducted atrial depolarization, the coupling interval was 325-380 
ms. This coupling interval would under normal circumstances be sufficiently long to 
result in a ventricular contraction. A possible explanation to this phenomenon, 
suggested by Zhao et al 183, is a prolonged repolarization in the AV- node or in the 
ventricle causing a prolonged QT-interval with a resulting BB. 
 
 
 
6.2 ISOLATED FETAL AVB AND STEROID TREATMENT (PAPER II) 
 
There are very few previous studies regarding transplacental steroid treatment to 
fetuses with congenital heart block, especially concerning possible treatment effects.  
We described the outcome in the largest reported data set of fetuses with isolated 
second- and third-degree AVB. The main objectives were to compare the outcome in 
steroid-treated versus untreated patients, identify risk factors associated with a poor 
outcome and describe treatment practices.  
 
The results of our study confirmed the impression that there is no consensus regarding 
treatment with fluorinated steroids to fetuses with second- or third-degree AVB. 
Almost all patients were treated at some centers, whereas at others no patients received 
treatment, independent of the fetal status at diagnosis. At the outset, we expected that 
the more diseased fetuses would be more likely to get steroid treatment but that did not 
seem to have been the case. Apart from a small difference in GA at time of diagnosis 
the groups were comparable, allowing us to analyze the effect of steroids on outcome, 
adjusting only for the difference in GA at diagnosis in a logistic regression model. We 
could see no significant differences in survival at birth or at 1 month of age, not even 
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when the comparisons were restricted to the group of antibody exposed fetuses; a group 
that, at least theoretically, would be most likely to benefit from treatment. 
 
Our results in perspective 
Given the rarity of the disease, there are unfortunately no prospective, blinded studies 
comparing treatment effects and very few retrospective studies. Our results do, 
however, contrast with those of Jaeggi et al 125, who described a treatment effect in 
comparison with an untreated historical cohort. The most surprising result of their study 
was a mortality rate close to 50% among the untreated, whereas 1- month survival in 
the treated group was similar to the overall survival in our study. Examining the data by 
Jaeggi et al, demonstrated that risk factors shown in our study to be associated with a 
poor outcome, were more frequent in the untreated group; thus perhaps explaining 
some of the difference. In another study by Lopez et al 184, the largest single-center 
study so far, 51/57 (89 %) of fetuses with isolated second- or third degree AVB, not 
receiving steroid treatment, had a 1-month survival of 80%. Half of the steroid treated 
patients (3/6) died before 1 month, in contrast to the high survival rate in our study. 
 
Transplacental steroids- effective or not? 
Even if our results do not indicate a beneficial effect of transplacental steroid treatment, 
the retrospective and multicenter design cannot rule out a possible effect in subgroups 
of patients. A simple power calculation tells us that we would need > 500 patients to 
detect a 50% reduction in mortality at a 5% significance level with 80% power. This 
means that there is a risk that we have failed to detect smaller differences between the 
groups, as this study is “underpowered” in that sense. Furthermore there was a 
considerable variation in dosage, gestational age at initiation of therapy as well as 
treatment duration, which could not be controlled for in the comparisons.  
 
In agreement with previous reports 116-118 reversion from incomplete AVB to 1:1 
conduction after steroid treatment was observed in a few cases, namely in 3 of 7 
antibody exposed second-degree AVB, and in a further 2 of 6 (5 antibody exposed) 
cases with AVB II-III. However, only 2 of those with known outcome were still in 
sinus rhythm at FU. There are to our knowledge no reports of spontaneous reversion of 
an incomplete AVB exposed to maternal autoantibodies. This could, in our opinion, 
indicate a possible beneficial effect of maternal steroids in this restricted group. 
 
Risk factors associated with a poor outcome 
 
Gestational age 
We found a correlation between low GA at the time of diagnosis and the risk of 
intrauterine and/or neonatal death in our study. In the study of Jaeggi et al, with 
comparable average GA at diagnosis, there was no significant difference between 
survivors and non-survivors. Patients in the Lopez study were diagnosed later than our 
patients (average 29 vs 24 weeks). Obviously, gestational age cannot be a risk factor 
per se (a part from a possible difference as to when the heart block will actually 
develop), but the earlier the detection, the larger the proportion of fetuses at risk. Hence, 
some of the differences will likely depend on differences in ultrasound screening 
programs and midwife surveillance. 
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Other risk factors  
Fetal hydrops, 28, 139, 185 impaired left ventricular function 28 and low heart rate 71 are all 
variables previously shown to be associated with a poor outcome, findings consistent 
with the results of our study . In addition to the contribution of increased risk by each of 
these factors, we studied the impact of having at least one risk factor, including low 
gestational age at time of diagnosis. Intrauterine and neonatal mortality was 22 and 
18% respectively, if at least one risk factor was present, but only 2 and 3% in those 
without risk factors. This has, to best of our knowledge, not been studied before but 
could be useful in the counseling and management of this patient group, enabling a 
better risk stratification.  
 
Due to patient loss to FU as well as a substantial variation in FU time, long term 
outcome in terms of morbidity, could not be evaluated on a group level. The proportion 
of dilated cardiomyopathy (DCMP) in our study may therefore be underestimated. 
Other studies report, however, a varying prevalence of DCMP; from 28% in the study 
by Villain 186 to around 5-10% in others 187-189. 
 
Study limitations 
As mentioned above, the retrospective study design, gave limited control over 
especially details regarding exposure to treatment. Dosage, duration and GA when 
treatment started varied in the group and could hence not be controlled for. There is a 
non- negligible risk that we have failed to detect small differences between the groups, 
due to the relatively small study group, the presence of missing data in some of the 
variables and the retrospective study design. A multicenter format also complicates data 
control.   
 
 
6.3 CLINICAL PATHOGENESIS AND ANTIBODY EXPOSURE (PAPER III) 
 
Little has been known about the long term outcome of fetal exposure to maternal anti-
Ro/SSA autoantibodies in individuals who do not develop heart block early in life. 
Previous studies are small with a limited number of patients and limited follow-up. 
 
In this study of preschool children, previously exposed in utero to maternal 
autoantibodies, we found that the group with prenatal AV time interval prolongation 
(group A), also had longer PR intervals on ECG compared to those with normal 
prenatal findings (group B). About 10%, all belonging to group A, had progressed to 
first-degree AVB at follow-up, in spite of a normal ECG at birth and/or 1 month of age. 
It was unexpected to find this fluctuation in PR intervals, with a normalization at birth 
or at 1 month of age in all subjects, and a progression in some patients later in life. The 
findings on ECG were confirmed by very similar results in the Holter recordings, 
where one additional patient with clear but intermittent PR interval prolongation had a 
normal PR interval on ECG, showing that conduction abnormalities can fail to be 
detected unless a Holter ECG is included. These are, to the best of current knowledge, 
new findings that could support a hypothesis claiming that exposure to maternal 
autoantibodies, causing only a minor injury, can be subtle and easily escape detection. 
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A previous prospective controlled study of anti SSA/Ro exposed newborn infants 
showed a 10% (5/51) prevalence of AVB I at birth. Three of these patients remained in 
AVB I and 2 normalized the PR interval at FU at 1 year of age 190. In another 
prospective, multicenter study 143, nine percent (4/46) of anti -SSA/Ro exposed children 
had PR interval prolongation (>140 ms) at 20-90 days of age and 0/26 patients at FU at 
1 year of age. In the PRIDE study of 98 antibody exposed fetuses, 2 developed AV 
time interval prolongation between GA 16 and 26 weeks (upper limit set to > 150ms), 
both were treated with dexamethasone and were said to “reverse” to normal AV 
intervals within 1 week after treatment was given. Both had normal PR intervals at 
birth and 1 year of age. In contrast, another patient from the same study who had 
normal AV intervals throughout the gestation, had AVB I at 3 years of age 111. In a 
study by Costedoat-Chalumeau et al87, 58 patients were exposed to anti-SSA/Ro 
antibodies and in the 20 of these cases where an ECG was performed at FU, all had a 
normal ECG without PR interval prolongation. Possible explanations of the 
discrepancy between the results of our study compared with those of others could be: 
(1) smaller sample sizes and/or (2) loss to FU in the above studies or (3) a longer FU in 
our study. Moreover, it is always hypothetically possible that our results appeared by 
chance. This is in my opinion unlikely, as we know that antibody exposure can cause 
impaired AV conduction both in fetal life and after birth. There are, however, only a 
few previously documented examples of postnatal progression from normal sinus 
rhythm at birth to first-degree AVB in cases associated with exposure to maternal 
antibodies146, 191. 
 
Is it important to diagnose first-degree AVB in these children?  
Even if we have good reasons to believe that the majority of the children will not 
progress to complete AVB, a follow-up of this patient group was lacking and our 
results provide clinical evidence to the pathogenesis of development of AVB. It 
furthermore confirms that the outcome analyses of antibody exposure cannot be 
simplified to a categorical outcome in terms of did/ did not develop CAVB, but should 
rather be seen as a broad continuum from a barely perceptible affection (like first-
degree AVB) to fulminant disease. In a study by Bergman et al27, a subgroup of 
antibody exposed individuals were diagnosed with complete AVB after the perinatal 
period (aged 4 months to 43 years), supporting the hypothesis of a late and gradual 
progression to complete AVB. It must be said however, that to date no cohort of 
antibody exposed individuals have been followed prospectively into adult age.  
 
Myocardial performance 
In order to detect even subclinical impact on cardiac function by exposure to maternal 
autoantibodies, a complete echocardiographic study was performed on our patients. We 
could see that almost all observations were within normal limits. There was, however, a 
small difference between groups, in that patients from group A had higher MPI, 
possibly reflecting a reduction in the ventricular function as a consequence of a more 
pronounced impact of antibody exposure in some patients. The observed difference in 
MPI only showed a weak correlation with PR interval prolongation. These minor 
differences in MPI are most likely not very relevant from a clinical point of view, but 
they are interesting from a pathophysiological perspective as they are in line with our 
previous observations where the isovolumetric contraction time (ICT) interval was 
prolonged in antibody exposed fetuses 65. There are also other clinical observations 
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supporting a hypothesis of a myocardial process following antibody exposure, without 
a concomitant advanced degree of AVB 113, 192 193. These clinical observations are in 
turn supported by a previous study in an animal model where pups exposed to 
antibodies to the p200 stretch of Ro52 developed first-degree AVB. These specific 
cloned autoantibodies were furthermore shown to bind to cardiomyocytes causing 
dysregulation of the calcium balance with subsequent loss of contractility48. 
However, we still need to elucidate the long term outcome of having been exposed to 
maternal autoantibodies in fetal life, for those developing only a minor conduction 
abnormality persisting into pre-school age.     
 
Study limitations 
The sample size in this study was relatively small, although larger than most similar 
previous studies. Another limitation is the lack of an unexposed control group. 
 
  
6.4 PACEMAKER TRATMENT AND COMPLETE AVB (PAPER IV) 
 
We performed a nationwide, retrospective study describing the outcome in one of the 
largest datasets of young patients with isolated complete AVB and PM treatment. 
 
As this cohort only included patients who survived to pacing therapy, it excluded 
potential non-survivors who did not benefit from therapy and the study therefore does 
not estimate survival and early morbidity in congenital or complete AVB as a whole. 
 
Survival was 96% at FU after approximately 9 years of pacing. Overall, this result 
compares well with previous studies. In a comparable single center study by Villain et 
al186, 105/111 underwent PM treatment for > 6 months with a survival rate of 95% after 
median 10 years of PM treatment. In a study by Kim et al194 all 63 patients were alive 
after PM treatment for a median duration of 10 years, but patients with cardiac 
dysfunction prior to PM implantation were not included. Udink ten Cate et al195 studied 
111 patients with CAVB and PM treatment in a retrospective multinational, multicenter 
setting. Three patients died and 2 received a heart transplant, giving a survival rate of 
95% at 10 years of FU; however, 3/5 did not survive to 6 months of PM treatment. 
 
Apart from a shorter duration of pacing in the AB- group we could not detect any 
differences in LVF between AB- and AB+ at follow-up. This was, however, after any 
intervention (CRT or medication) due to development of LV dysfunction. Patients who 
died were excluded in the comparison, meaning that the comparison did not evaluate 
antibody exposure per se.  
 
Looking at variables with a possible influence on LVF, only age at diagnosis had a 
significant impact on LVF with a higher LVEDD z-score in age< 1 month at diagnosis, 
whereas time of exposure to pacing, AB-exposure, and gender had no significant 
impact on outcome. To the best of our knowledge, only Villain et al have previously 
compared the outcome of AB+ vs AB-, showing that only AB+ patients developed LV 
dysfunction; however they did not compare the impact on LVF at a group level. The 
advantage of their study was that information on AB exposure was present in all cases, 
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compared with in 88% of our cases. Given the close relationship between AB-exposure 
and age at diagnosis, our finding of an increased LVEDD z score in those diagnosed    
< 1 month of age, points to a possible impact of either AB exposure or diagnosis at an 
early age. In agreement with the study by Kim et al194, no difference in LVF between 
long- term and short- term pacing at FU could be seen in our study.   
 
 
Dilated cardiomyopathy and predisposing factors 
 
Study cohort size 
The problem of identifying predictors of a poor outcome in a rare disease like CAVB is 
obvious; not even the largest studies like the one of Villain et al, will have more than 
around 5-15 patients in each cohort developing DCMP. In our study nine patients (8%) 
developed LV dysfunction (equivalent to DCMP in other studies); a result that 
compares well with previous studies188, 194-200 Interestingly, none of our patients had a 
normal echo before PM implantation and none of those with a normal echo before PM 
therapy developed LV dysfunction. Furthermore, all were diagnosed in fetal life or just 
after birth and 6/7 tested, were associated with autoantibody exposure. The gender 
distribution was 2:1 male to female.  
 
Exposure to maternal autoantibodies and early diagnosis 
Other studies have shown that patients developing DCMP are predominantly diagnosed 
before 1 month of age186, 195. Combined with the fact that 80- 90% of those early-
diagnosed are exposed to maternal autoantibodies39, 124, 186, 201; this means it is a difficult 
and maybe even less important task to “prove” the causality between AB exposure and 
development of DCMP. Most studies have a retrospective design and encompass 
several decades. Consequently, information on AB-status will often be lacking and 
sometimes even incorrect, due to lower precision in detecting antibodies in the past, 
whereas information on age at diagnosis often will be present. This leads to a “dilution” 
of the data set and contributes, in our opinion, to a stronger correlation between age of 
diagnosis and outcome than between antibody exposure and outcome. However, the 
fact that the majority of individuals with early diagnosis/antibody exposure do not 
develop DCMP indicates that these characteristics may be a prerequisite in most cases 
but other factors are needed to develop DCMP.    
 
Cardiac status prior to PM implantation 
None of our patients who developed DCMP had a normal LVF before PM 
implantation, but only 3/8 had developed LV dysfunction, as defined in this paper. 
Information on the cardiac status prior to implantation was often lacking in previous 
studies but Villain et al reported that 12/16 of their DCMP- cases had this diagnosis 
before a PM was implanted. Applying the age correlated FS z-score on the data 
presented by Moak et al202, 12/16 had z-score values below –2. These results indicate 
the importance of thoroughly evaluating the pre-intervention LVF when predicting the 
outcome and analyzing the impact of other variables.  
 
Gender 
We found, unexpectedly, that the time from diagnosis to PM implantation was 
significantly shorter in boys than in girls, especially in the AB+ as well as those 
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diagnosed < 1 month of age. With the assumption that this could reflect a gender 
difference in the pre-implantation status we compared LVF measures and found that  
LVEDD z-scores were higher and FS z-scores lower in boys. Furthermore, HR at birth 
was lower in boys. This could indicate a gender difference in the degree of disease in 
our study group and a possible interpretation of these findings is that the boys were 
given a pacemaker at an earlier age simply because they were in a more compromised 
cardiac situation than the girls. 
 
In the few studies where data on AB exposure and gender are present, there seems to be 
a rather equal gender distribution among the AB exposed. Regarding a possible 
difference in morbidity or mortality, the picture is less clear, but in a study by Eronen et 
al124 where 91 patients with CAVB were diagnosed in fetal life or as neonatals, only 
31/91 (34%) were males but 12 (39%) had a poor outcome vs 22% of the females. In a 
further two reports, 75 and 100% of patients developing DCMP188, 203 were males, 
without this having been particularly discussed or highlighted. In an effort to see if a 
Medline search could give some indication in this matter, we performed a search for 
studies reporting on young patients diagnosed with DCMP. We found 13 studies and 1 
case report124, 186-189, 194, 195, 197, 199, 200, 203-205, the present study included,  where the 
definition of DCMP was acceptably transparent and unequivocal with a total of 107 
patients meeting the criteria. Surprisingly, information on gender was presented in only 
about half of the studies. Looking closer at the studies containing data on gender 
distribution, 38 males versus 16 females had developed DCMP. Taking these data into 
consideration, it is difficult to exclude a possible gender effect on morbidity or 
mortality. A Medline search is obviously not comparable to a regular study and hence 
the results must be interpreted with caution. It is furthermore impossible to exclude the 
risk that the data of some patients have been published in more than one study. It would 
however be interesting to put the hypothesis of a gender component involved in the 
development of the clinical picture in the context of a larger prospective and blinded 
study. 
 
Pacing 
We investigated the time from diagnosis to PM implantation and discovered that there 
has been a shift towards a considerably shorter time interval between diagnosis and PM 
implant over the last decades. This has to our knowledge not been studied previously 
and the results support the general impression that guidelines advocating pacing 
therapy at an earlier age than before are being implemented. Our data also support the 
hypothesis that patients who were paced in the early period were more diseased, in that 
they had significantly higher LVEDD z-scores and lower FS z-scores than patients in 
the late period and our interpretation is that asymptomatic patients were given a PM at 
a later age in the early period. 
 
It is an ongoing debate as to whether and to what extent the type of pacing, and 
especially right ventricular pacing, plays a role in the development of DCMP. About 
20% in this cohort had LV pacing as a first system and we aimed at studying the 
importance of pacing mode /type and site with respect to outcome. There were, 
however, differences in the baseline characteristics between the groups, which made a 
fair comparison impossible. Several studies have shown that impaired LV function and 
intra-ventricular dyssynchrony, is mainly observed in pacing from the RV apex163, 206, 
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207. In the multicenter study by Janusek et al207 where LVF- and LV dyssynchrony 
measures were important outcome variables, LV function and LV synchrony was 
superior in individuals paced at the LV apex or the LV midlateral wall. FS values were, 
however, compared without taking into account a significant difference in age between 
the groups. Correcting the EF and FS values for age, creating a FS a-score or a similar 
EF correction for age or body surface, could in our opinion have given a more correct 
picture of the differences, even if the data as a whole support the concept of more 
favorable hemodynamics in LV pacing, at least compared with RV apical pacing.  
More importantly however, there is a problem of translating these observations into 
clinical practice, knowing that around 90% of the CHB patients do not have LV 
dysfunction at FU, irrespective of type of pacing, making it obvious that other factors 
than pacing site plays a role in the development of DCMP in selected groups of 
patients. Many cardiologists would however, if possible, probably avoid RV apical 
pacing. 
 
 
Complications to pacing therapy 
Most previous studies did not compare endocardial and epicardial pacing in isolated 
CAVB, but mixed study groups with postoperative AVB and/or CAVB associated with 
congenital heart disease. Age span, definitions of complications/re-interventions and 
time of FU also varied considerably, making a direct comparison with our study 
difficult.  
 
At least one re-intervention was necessary due to PM system related complications in 
24% of our patients, compared with 42% (11/26) in a study by Balmer et al208; one of 
the few previous studies of exclusively isolated CAVB with information on PM related 
complications. As in previous studies208-210, lead related problems (fracture, insulation 
break or dislodgement) were the most common causes for re-interventions in our study, 
followed by infections. We found that PM implantation before 1 month of age was 
strongly associated with procedure related complications. This is line with at least one 
previous study on pacing related complications156, though this was in a group where the 
majority had CHD or postoperative CHB. The occurrence of complications 
necessitating a re-intervention was not significantly different between the epicardial- 
and endocardial groups, as opposed to results in the majority of previous studies on 
mixed populations where epi-pacing was less favorable157, 209, 210. A possible reason for 
this could be the non-separation of isolated CAVB and structural heart disease when 
comparing the systems in previous studies. Another study focusing only on lead related 
problems failed to show any differences between the groups211. 
 
Strengths and Limitations 
The retrospective study design is obviously a disadvantage, especially regarding the 
lack of control of data and maybe most importantly, of the outcome variables. It is well 
known that measuring FS and LVEDD does not tell the whole truth about left 
ventricular function. A prospective FU with a more sophisticated evaluation of LVF 
(3D echo, spackle tracking, and diagnostics of dyssynchrony) as well as a control group 
would of course have been a better alternative. We aimed at comparing the possible 
impact of different kinds of pacing modes and types but a non-randomized study like 
this does not permit controlling for differences in morbidity (LVF) prior to PM therapy. 
 52 
This would make comparisons non-meaningful. Furthermore, we could not study the 
impact of pacing site on LVF, as information of the exact position of the pacing 
electrode in the ventricle was present in less than half of the patients. Missing values in 
some outcome variables can have affected the precision of the estimates. Recognizing 
the difficulties in ruling out a possible importance of non-significant results in a 
multifactorial context and a retrospective study design, it is possible that we have 
underestimated the importance of one or more tested variables when evaluating their 
impact on outcome. The strength of the study is above all its character of a national 
cohort where in our opinion the process of identification and selection of patients is 
transparent. Through use of the unique personal identification numbers used in Sweden, 
we have minimized the risk of not having identified patients meeting the inclusion 
criteria.  
 
Conclusion 
Our study confirms previous results of showing an excellent outcome in this group of 
patients with complete AVB and PM treatment. Interestingly, we could see that none of 
the patients who developed LV dysfunction/DCMP had a normal LVF prior to PM 
treatment, indicating the importance of taking into account the cardiac status prior to 
pacing when predicting the long term outcome. We also report on a gender difference 
in time from diagnosis to PM treatment as well as more impaired LVF values in males 
than females prior to PM treatment. Given the retrospective character of the study, 
these findings need to be further elucidated, preferably in a prospective setting.  
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7 CONCLUSIONS 
 
With current Echo Doppler techniques underlying substrates of fetal bradycardia can be 
differentiated with accuracy and precision; even in mid-gestation when there was a high 
resemblance between benign atrial bigeminies and second-degree AVB. Sinus 
bradycardia had a high prevalence of associated disease, emphasizing the importance of 
postnatal follow-up in this group.  
 
Transplacental treatment of fetuses with third-degree AVB did not improve survival, 
nor did it affect AV-conduction. Risk factors of a poor outcome were identified and the 
presence of at least one of them at the time of diagnosis, had a substantial impact on 
mortality, with a 10-fold increase at birth and a 6-fold increase at 1 month of age. The 
results do, however, not exclude a treatment effect in subgroups of patients. 
Furthermore, we observed a possible treatment effect in terms of improved conduction 
properties in second-degree AVB, although numbers are small. 
 
Pre-school children exposed in utero to maternal SSA-Ro autoantibodies and who 
developed fetal AV time interval prolongation but not complete AVB, could develop 
first-degree AVB even if ECG was normal at birth or 1 month of age. Discrete signs of 
impaired left ventricular function in this group could be an effect of antibody exposure. 
The results demonstrate the variable disease expression as a result of exposure to 
maternal autoantibodies and give new insights in the clinical pathogenesis of congenital 
heart block. The implications of the findings are, in my opinion, a follow-up restricted 
to individuals with conduction abnormalities.  
 
Children with complete AVB who survive the perinatal period have a very good 
prognosis with an excellent survival rate of 96% after 9 years of pacemaker treatment. 
The majority had no complications from pacing therapy during this period. Impaired 
left ventricular function before pacemaker treatment as well as diagnosis < 1 month of 
age, were risk factors for a poor long term outcome with ´development of left 
ventricular dysfunction. The results indicate that patients with congenital heart block 
may have a different outcome compared with patients who develop heart block later in 
life, but also that cardiac status before treatment is an important predictor. 
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8 SUMMARY OF THE THESIS IN SWEDISH 
 
Medfött hjärtblock är en ovanlig sjukdom som i de flesta fall drabbar barn till kvinnor 
som bär på vissa antikroppar vilka under graviditeten överförs till fostret och i en del 
fall innebär att hjärtat angrips. Ibland kan även andra organ påverkas, men dessa 
effekter är oftast övergående och ofarliga. Av hittills okända anledningar är det bara ca 
2% av barnen vars mödrar bär på antikroppar som utvecklar hjärtblock; de övriga tros 
vara friska även om en del forskningsresultat tyder på lindrigare påverkan i vissa fall. 
Medfött hjärtblock utvecklas oftast redan i fosterlivet och leder till att de impulser som 
uppstår i sinusknutan i hjärtats övre del inte kan fortledas till hjärtats kammare på 
vanligt sätt utan blockeras i övergången mellan förmak och kammare, i den s k AV- 
knutan, som är ett slags omkopplingsstation i hjärtats impulsspridningssystem.  
 
 
Om ett hjärtblock uppstår leder det till att pulsen 
sänks kraftigt; från ca 110-150 till 50-70 slag per 
minut. Graden av påverkan avgör fostrets och 
barnets framtid. Det är emellertid inte bara 
hjärtats impulsspridningssystem som kan 
påverkas, även själva hjärtmuskeln kan utsättas 
för angrepp (inflammation) och i värsta fall 
uppstår hjärtsvikt och fosterdöd. De barn som 
överlever (ca 70-85%) kommer förr eller senare 
att behöva få en pacemaker (PM); en behandling 
som är livslång. 
 
 
 
I en del fall ställs diagnosen genom screeningundersökningar av gravida som man vet 
bär på antikroppar och därför har en viss risk att föda barn med hjärtblock. I andra fall 
sker upptäckten efter att man på mödravårdscentralen uppmätt misstänkt låg puls hos 
fostret. Den slutgiltiga diagnosen ställs med hjälp av ultraljud av fostrets hjärta. 
Diagnostiken ställer höga krav på precision och noggrannhet; en felaktigt ställd diagnos 
kan antingen leda till onödig behandling, som kan vara skadlig för fostret eller en 
missad chans till -i vissa fall- livsviktig behandling av ett s k andra gradens hjärtblock; 
ett mellansteg på väg till komplett hjärtblock. 
 
Många försök har gjorts att ge kortison- (steroid) behandling till den gravida kvinnan 
med avsikten att medicinen via moderkakan skall nå fostret och sedan dämpa den 
inflammation man vet kan drabba hjärtat. Med dagens kunskap finns dock ingen 
effektiv behandling att erbjuda när ett komplett hjärtblock väl har utvecklats, även om 
en del forskare tycker sig ha sett en förbättrad överlevnad med steroidbehandling. 
Resultaten bygger dock på enstaka studier med låga patientantal och professionen är 
inte enig i om behandling bör användas eller ej. Behandlingen kan nämligen ge 
oönskade effekter hos såväl mor som barn. Man tror att de allra flesta barn som 
exponerats för antikroppar i fosterlivet utan att utveckla hjärtblock ej heller kommer att 
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göra det senare i livet. Dock har en del studier visat att barn kan utveckla en lindrig 
störning och fördröjning av impulsspridningen (hjärtblock av första graden) under 
fosterlivet, vilket emellertid verkar vara ett övergående tillstånd i de flesta fall. 
Pacemakerbehandling är visserligen livräddande i  många fall, samtidigt har man sett 
från tidigare studier att en del barn drabbas av hjärtsvikt trots PM-behandling. Det är 
oklart vilka faktorer som påskyndar en sådan utveckling. 
 
Mitt avhandlingsarbete belyser huvudsakligen fyra frågeställningar:  
- Kan man med nuvarande ultraljudsteknik på ett tillfredsställande sätt ställa diagnos 
hos foster med långsam hjärtrytm?  
-Påverkas överlevnad och sjuklighet hos foster med hjärtblock av steroidbehandling 
och vilka är riskfaktorerna för dödlig utgång? 
-Hur mår barn i förskoleåldern som under fosterlivet utsattes för antikroppar från 
modern men ej utvecklade komplett hjärtblock? Finns några kvarvarande tecken till 
påverkan hos den minoritet som uppvisade hjärtblock av första graden i fosterlivet? 
-Hur går det för barn med medfött hjärtblock och pacemakerbehandling? Har de ett 
annat utfall än de som utvecklar hjärtblock senare? 
 
Metoder och Resultat: 
I studie I analyserades ultraljudsundersökningar av 65 barn från upptagningsområde 
Stockholm-Uppsala och vi fann att en korrekt diagnos hade ställts i samtliga fall utom 
ett samt att man i samtliga fall kunde skilja godartade från potentiellt farliga och 
behandlingskrävande rytmrubbningar. 
 
I studie II jämfördes 175 fall av hjärtblock diagnostiserade under fosterlivet; data kom 
från 28 centra i 15 länder. Nittioen procent var levande födda. Ingen skillnad i 
överlevnad kunde ses mellan dem som fått behandling med steroider jämfört med 
obehandlade. Riskfaktorer kopplade till dödlighet kunde identifieras. 
 
I studie III undersöktes 57 barn med ultraljud av hjärtat, ekg samt långtids-ekg och 
resultaten visade att ca 10% hade en begränsad påverkad på impulsspridningen i hjärtat. 
Det fanns också tecken till en mycket diskret påverkan av hjärtfunktionen. Alla barn 
var i övrigt hjärtfriska. 
 
I studie IV jämfördes data från samtliga unga personer med hjärtblock i Sverige, 
diagnostiserade mellan 1980 och 2011. Knappt två tredjedelar hade medfött hjärtblock 
och av dessa var 90% kopplade till antikroppar. Överlevnaden var 96% efter i 
genomsnitt nio års pacemakerbehandling. Åtta procent utvecklade nedsatt hjärtfunktion 
och av dessa hade samtliga medfött hjärtblock.  
 
Sammanfattningsvis visar studie I att det med en tillfredställande precision gick att 
ställa rätt diagnos på barn med långsam hjärtrytm. I studie II sågs ingen effekt på 
överlevnad av steroidbehandlade hjärtblock under fosterlivet men riskfaktorer kopplade 
till död kunde identifieras. Tio procent av de barn som hade exponerats för antikroppar 
från modern hade utvecklat hjärtblock av första graden vid uppföljning i förskoleåldern 
(studie III). Barn och unga med pacemakerbehandling hade en utmärkt prognos, dock 
fanns en koppling mellan tidig diagnos och påverkan av hjärtfunktionen (studie IV). 
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9 FUTURE PERSPECTIVES 
Although congenital heart block is clearly associated with the passive transplacental 
transfer of maternal autoantibodies and studies of the pathogenesis have made great 
progress over the last years, we are still far from understanding why only 2% of fetuses 
exposed to antibodies develop CHB. Current hypotheses involve fetal and maternal 
factors as well as environmental and genetic components. Further studies are, however, 
needed to elucidate the mechanisms involved in “transforming” a status of exposure to 
autoantibodies, without apparent impact on the fetus, to the development of CHB and 
neonatal lupus syndrome, with all its components. Successful therapeutic interventions 
will depend on a profound understanding of the mechanisms leading to disease. 
 
The ideal scenario would of course be to prevent heart block from occurring, possibly 
by blocking the transfer of autoantibodies to the fetus during pregnancy, or impeding 
their effect on the fetus by identifying the key players in that process. Current 
therapeutic interventions have not been successful thus far. Treatment strategies aiming 
at intervening when the fetuses show signs of impaired AV conduction, i.e. developing 
first-degree AVB, have been tried. The problem is that we do not know if the treatment 
is useful, as only about 10% of those with fetal exposure to maternal autoantibodies had 
developed first-degree AVB at follow-up, whereas AV time interval prolongation 
appears to be transitory in the majority of cases, as our study (III) showed. 
Furthermore, we have no evidence to support a hypothesis that these pre-school 
children with first-degree AVB are at risk of progressing to complete AVB later in life. 
This, combined with the fact that there is clear evidence for a sometimes very rapid 
progress of conduction disease from normal SR to complete AVB in less than a week, 
but possibly even much faster than that, suggests that those who develop complete 
AVB do so at a higher “speed” and therefore may be out of reach for treatment.   
 
So, a challenge for the near future is to individuate the best methods for identifying 
individuals who really are at risk of progressing to a complete and irreversible heart 
block and to distinguish these individuals from those who will “only” experience AV 
time interval prolongation, transitory or not. One of the problems is that we do not 
know which prolongation of the AV interval, irrespective of methods used, is too long. 
Is an extreme first-degree AVB too long and should this always require treatment? A 
research project monitoring fetuses at risk in the critical period from around 15 to 26 
weeks would probably provide new insights and knowledge. Such an approach is 
obviously connected with possible risks of interfering psychologically with normal 
pregnancies in a group where around 98% will give birth to a child without CHB.  
 
Once a CHB has developed through exposure to autoantibodies, it is considered 
irreversible and the affected individuals will need lifelong pacemaker treatment. As we 
have seen from our study (IV) and others, the absolute majority have a very good 
prognosis. However, we need to further study the subgroup of patients who, in spite of 
PM treatment, will develop dysfunction of the left ventricle. Is early diagnosis a risk 
factor and is the association with antibody exposure just as strong? Is there a gender 
difference involved? While most patients seem to tolerate RV pacing well, is there a 
subgroup of patients, maybe with impaired LV function prior to PM treatment, who 
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would benefit from LV pacing? It is very unlikely that we will ever have blinded, 
randomized studies comparing different types of pacing, but even with a retrospective 
study design with a cross-sectional follow-up and a multicenter approach (such as the 
one by Janousek et al207), we could gain knowledge. The quality of the dataset must 
however improve, in the sense that full information on exposure to autoantibodies, 
gender and, above all, echocardiography prior to pacing must be present to qualify for 
inclusion in future studies. In order to evaluate current treatment strategies in young 
patients with isolated CHB, we also need to evaluate the adult population. Apart from 
single smaller studies, more systematic data on outcome are lacking. 
 
Future pacing strategies 
 
Leadless pacing 
Pacing in children is still technically challenging and entails a considerable risk of 
intervention-related complications, many of which are due to pacing lead problems. A 
recent study in an adult population with self-contained leadless cardiac pacemakers 
showed promising preliminary results with few early complications212. It is, however, 
still far from being an accessible tool in the pediatric population as the delivery device 
and catheters are not adapted for children. Furthermore, the device in its actual form is 
tailored for implantation in the RV apex, which is a pacing site we wish to avoid in 
children. With further technical development, this device may be adapted to alternate 
pacing sites and to a pediatric population. 
  
Biological pacing 
Research in the field of human biological pacing has been increasing over the last 
years, with interesting results from animal studies. The current understanding of the 
method implies the usage of gene- and cell-therapy for delivery and introduction of 
pacemaker function to the heart213. However, there is a long way to go before problems 
connected with safety and efficacy can be resolved and biological pacing becomes a 
reality for the pediatric population. 
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